Document:

Exhibit 4.1

        

       

        

      EXECUTION VERSION

    

     

    CONTINGENT VALUE RIGHTS AGREEMENT

     

    by and between

     

    BRISTOL-MYERS SQUIBB COMPANY

     

    and

     

    EQUINITI TRUST COMPANY

     

    Dated as of November 20, 2019

     

    
      
        

    

    
    TABLE OF CONTENTS

     

    	
            ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

          	
            1

          
	 	
            Section 1.1

          	
            Definitions

          	
            1

          
	 	
            Section 1.2

          	
            Compliance and Opinions

          	
            8

          
	 	
            Section 1.3

          	
            Form of Documents Delivered to Trustee

          	8
	 	
            Section 1.4

          	
            Acts of Holders

          	
            9

          
	 	
            Section 1.5

          	
            Notices, etc., to Trustee and Company

          	
            10

          
	 	
            Section 1.6

          	
            Notice to Holders; Waiver.

          	
            11

          
	 	
            Section 1.7

          	
            Conflict with Trust Indenture Act

          	
            11

          
	 	
            Section 1.8

          	
            Effect of Headings and Table of Contents

          	
            11

          
	 	
            Section 1.9

          	
            Benefits of Agreement

          	
            11

          
	 	
            Section 1.10

          	
            Governing Law

          	
            12

          
	 	
            Section 1.11

          	
            Legal Holidays

          	
            12

          
	 	
            Section 1.12

          	
            Separability Clause

          	
            12

          
	 	
            Section 1.13

          	
            No Recourse Against Others

          	
            12

          
	 	
            Section 1.14

          	
            Counterparts

          	
            13

          
	 	
            Section 1.15

          	
            Acceptance of Trust

          	
            13

          
	 	
            Section 1.16

          	
            Termination

          	
            13

          
	 	 	 	 
	
            ARTICLE 2 SECURITY FORMS

          	
            13

          
	 	
            Section 2.1

          	
            Forms Generally

          	
            13

          
	 	 	 	 
	
            ARTICLE 3 THE SECURITIES

          	
            14

          
	 	
            Section 3.1

          	
            Title and Terms

          	
            14

          
	 	
            Section 3.2

          	
            Registrable Form

          	
            15

          
	 	
            Section 3.3

          	
            Execution, Authentication, Delivery and Dating

          	
            15

          
	 	
            Section 3.4

          	
            [Intentionally Omitted]

          	
            16

          
	 	
            Section 3.5

          	
            Registration, Registration of Transfer and Exchange

          	
            16

          
	 	
            Section 3.6

          	
            Mutilated, Destroyed, Lost and Stolen Securities

          	
            19

          
	 	
            Section 3.7

          	
            Payments with Respect to CVRs

          	
            19

          
	 	
            Section 3.8

          	
            Persons Deemed Owners

          	19
	 	
            Section 3.9

          	
            Cancellation

          	
            20

          
	 	
            Section 3.10

          	
            CUSIP Numbers

          	
            20

          
	 	 	 	 
	 	
            ARTICLE 4 THE TRUSTEE

          	
            20

          
	 	
            Section 4.1

          	
            Certain Duties and Responsibilities

          	
            20

          
	 	
            Section 4.2

          	
            Certain Rights of Trustee

          	
            21

          
	 	
            Section 4.3

          	
            Notice of Default

          	
            23

          
	 	
            Section 4.4

          	
            Not Responsible for Recitals or Issuance of Securities

          	
            23

          
	 	
            Section 4.5

          	
            May Hold Securities

          	
            23

          
	 	
            Section 4.6

          	
            Money Held in Trust

          	
            23

          
	 	
            Section 4.7

          	
            Compensation and Reimbursement

          	
            23

          
	 	
            Section 4.8

          	
            Disqualification; Conflicting Interests

          	
            24

          
	 	
            Section 4.9

          	
            Corporate Trustee Required; Eligibility

          	
            24

          
	 	
            Section 4.10

          	
            Resignation and Removal; Appointment of Successor

          	24

    

    

    
      i

      
        

    

    	 	
            Section 4.11

          	
            Acceptance of Appointment of Successor

          	
            26

          
	 	
            Section 4.12

          	
            Merger, Conversion, Consolidation or Succession to Business

          	
            26

          
	 	
            Section 4.13

          	
            Preferential Collection of Claims Against Company

          	
            26

          
	 	 	 	 
	
            ARTICLE 5 HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY

          	
            27

          
	 	
            Section 5.1

          	
            Company to Furnish Trustee Names and Addresses of Holders

          	
            27

          
	 	
            Section 5.2

          	
            Preservation of Information; Communications to Holders

          	
            27

          
	 	
            Section 5.3

          	
            Reports by Trustee

          	
            27

          
	 	
            Section 5.4

          	
            Reports by Company

          	
            28

          
	 	 	 	 
	
            ARTICLE 6 AMENDMENTS

          	
            28

          
	 	
            Section 6.1

          	
            Amendments Without Consent of Holders

          	
            28

          
	 	
            Section 6.2

          	
            Amendments with Consent of Holders

          	
            29

          
	 	
            Section 6.3

          	
            Execution of Amendments

          	
            29

          
	 	
            Section 6.4

          	
            Effect of Amendments; Notice to Holders

          	
            30

          
	 	
            Section 6.5

          	
            Conformity with Trust Indenture Act

          	
            30

          
	 	
            Section 6.6

          	
            Reference in Securities to Amendments

          	
            30

          
	 	 	 	 
	
            ARTICLE 7 COVENANTS

          	
            30

          
	 	
            Section 7.1

          	
            Payment of Amounts, if any, to Holders

          	
            30

          
	 	
            Section 7.2

          	
            Maintenance of Office or Agency

          	
            31

          
	 	
            Section 7.3

          	
            Money for Security Payments to Be Held in Trust

          	
            31

          
	 	
            Section 7.4

          	
            Certain Purchases and Sales

          	
            32

          
	 	
            Section 7.5

          	
            Books and Records

          	
            32

          
	 	
            Section 7.6

          	
            Listing of CVRs

          	
            32

          
	 	
            Section 7.7

          	
            Product Transfer

          	
            32

          
	 	
            Section 7.8

          	
            Diligent Efforts

          	32
	 	
            Section 7.9

          	
            Confidentiality

          	
            33

          
	 	
            Section 7.10

          	
            Non-Use of Name

          	33
	 	
            Section 7.11

          	
            Notice of Default

          	
            34

          
	 	 	 	 
	
            ARTICLE 8 REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT

          	
            34

          
	 	
            Section 8.1

          	
            Event of Default Defined; Waiver of Default

          	
            34

          
	 	
            Section 8.2

          	
            Collection by the Trustee; the Trustee May Prove Payment Obligations

          	
            35

          
	 	
            Section 8.3

          	
            Application of Proceeds

          	36
	 	
            Section 8.4

          	
            Suits for Enforcement

          	
            37

          
	 	
            Section 8.5

          	
            Restoration of Rights on Abandonment of Proceedings

          	
            37

          
	 	
            Section 8.6

          	
            Limitations on Suits by Holders

          	37
	 	
            Section 8.7

          	
            Unconditional Right of Holders to Institute Certain Suits

          	
            38

          
	 	
            Section 8.8

          	
            Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default

          	
            38

          
	 	
            Section 8.9

          	
            Control by Holders

          	38
	 	
            Section 8.10

          	
            Waiver of Past Defaults

          	
            39

          

    

    

    
      ii

      
        

    

    	 	
            Section 8.11

          	
            The Trustee to Give Notice of Default, But May Withhold in Certain Circumstances

          	
            39

          
	 	
            Section 8.12

          	
            Right of Court to Require Filing of Undertaking to Pay Costs

          	39
	 	 	 	 
	
            ARTICLE 9 CONSOLIDATION, MERGER, SALE OR CONVEYANCE

          	
            40

          
	 	
            Section 9.1

          	
            Company May Consolidate, etc., on Certain Terms

          	
            40

          
	 	
            Section 9.2

          	
            Successor Person Substituted

          	
            40

          
	 	
            Section 9.3

          	
            Opinion of Counsel to the Trustee

          	
            41

          
	 	
            Section 9.4

          	
            Successors

          	
            41

          
	 	 	 	 
	
            ARTICLE 10 SUBORDINATION

          	
            41

          
	 	
            Section 10.1

          	
            Agreement to Subordinate

          	
            41

          
	 	
            Section 10.2

          	
            Liquidation; Dissolution; Bankruptcy

          	
            41

          
	 	
            Section 10.3

          	
            Default on Senior Obligations

          	
            42

          
	 	
            Section 10.4

          	
            When Distribution Must Be Paid Over

          	
            42

          
	 	
            Section 10.5

          	
            Notice by Company

          	
            43

          
	 	
            Section 10.6

          	
            Subordination Effective Notwithstanding Deficiencies with Respect to Senior Obligations: Waiver of Right to Contest Senior Obligation: Reinstatement of Subordination Provisions

          	
            43

          
	 	
            Section 10.7

          	
            Subrogation

          	
            44

          
	 	
            Section 10.8

          	
            Relative Rights

          	
            44

          
	 	
            Section 10.9

          	
            Subordination May Not Be Impaired by Company

          	
            44

          
	 	
            Section 10.10

          	
            Distribution or Notice to Representative

          	44
	 	
            Section 10.11

          	
            Rights of the Trustee

          	
            45

          
	 	
            Section 10.12

          	
            Authorization to Effect Subordination

          	
            45

          
	 	
            Section 10.13

          	
            Amendments

          	45

    

    

    Annex A — Form of Global Security

     

    Annex B — Form of Assignment and Assumption Agreement

     

    Note: This table of contents shall not, for any purpose, be deemed to be a part of this CVR Agreement.

     

    
      iii

      
        

    

    Reconciliation and tie between Trust Indenture Act of 1939 and Contingent Value Rights Agreement, dated as of November 20, 2019.

     

    	
            Trust Indenture Act Section

          	 	
            Agreement Section

          
	
            Section 310

          	
            (a)(1)

          	 	
            4.9

          
	 	
            (a)(2)

          	 	
            4.9

          
	 	
            (a)(3)

          	 	
            Not Applicable

          
	 	
            (a)(4)

          	 	
            Not Applicable

          
	 	
            (a)(5)

          	 	
            4.9

          
	 	
            (b)

          	 	
            4.8, 4.10

          
	 	
            (c)

          	 	
            Not Applicable

          
	 	 	 	 
	
            Section 311

          	
            (a)

          	 	
            4.13

          
	 	
            (b)

          	 	
            4.13

          
	 	
            (c)

          	 	
            Not Applicable

          
	 	 	 	 
	
            Section 312

          	
            (a)

          	 	
            5.1, 5.2(a)

          
	 	
            (b)

          	 	
            5.2(b)

          
	 	
            (c)

          	 	
            5.2(c)

          
	 	 	 	 
	
            Section 313

          	
            (a)

          	 	
            5.3(a)

          
	 	
            (b)

          	 	
            5.3(a)

          
	 	
            (c)

          	 	
            5.3(a), 8.11

          
	 	
            (d)

          	 	
            5.3(b)

          
	 	 	 	 
	
            Section 314

          	
            (a)

          	 	
            5.4, 7.11

          
	 	
            (b)

          	 	
            Not Applicable

          
	 	
            (c)(1)

          	 	
            1.2(a)

          
	 	
            (c)(2)

          	 	
            1.2(a)

          
	 	
            (c)(3)

          	 	
            Not Applicable

          
	 	
            (d)

          	 	
            Not Applicable

          
	 	
            (e)

          	 	
            1.2(b)

          
	 	
            (f)

          	 	
            Not Applicable

          
	 	 	 	 
	
            Section 315

          	
            (a)

          	 	
            4.1(a), 4.1(b)

          
	 	
            (b)

          	 	
            8.11

          
	 	
            (c)

          	 	
            4.1(a)

          
	 	
            (d)

          	 	
            4.1(c)

          
	 	
            (d)(1)

          	 	
            4.1(a), 4.1(b)

          
	 	
            (d)(2)

          	 	
            4.1(c)(ii)

          
	 	
            (d)(3)

          	 	
            4.1(c)(iii)

          
	 	
            (e)

          	 	
            8.12

          
	 	 	 	 
	
            Section 316

          	
            (a)(last sentence)

          	 	
            Not Applicable

          
	 	
            (a)(1)(A)

          	 	
            8.9

          
	 	
            (a)(1)(B)

          	 	
            8.10

          

    

       

    
      iv

      
        

    

    	
            Trust Indenture Act Section

          	 	
            Agreement Section

          
	 	
            (a)(2)

          	 	
            Not Applicable

          
	 	
            (b)

          	 	
            8.7

          
	 	
            (c)

          	 	
            Not Applicable

          
	 	 	 	 
	
            Section 317

          	
            (a)(1)

          	 	
            8.2

          
	 	
            (a)(2)

          	 	
            8.2

          
	 	
            (b)

          	 	
            7.3

          
	 	 	 	 
	
            Section 318

          	
            (a)

          	 	
            1.7

          

    

    

    Note: This reconciliation and tie shall not, for any purpose, be deemed to be a part of this CVR Agreement.

     

    
      v

      
        

    

    
    THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of November 20, 2019 (this
      “CVR Agreement”), by and between Bristol-Myers Squibb Company, a Delaware corporation (the “Company”), and Equiniti Trust Company,
      a limited trust company organized under the laws of the state of New York, as trustee (the “Trustee”), in favor of each person who from time to time holds one or more Contingent Value Rights
      (the “Securities” or “CVRs”) to receive cash payments in the amounts and subject to the terms and conditions set forth herein.

     

    WITNESSETH:

     

    WHEREAS, this CVR Agreement is entered into pursuant to the Agreement and Plan of Merger, dated as of January 2, 2019 (as amended, supplemented or
      otherwise modified in accordance with its terms, the “Merger Agreement”), by and among the Company, Burgundy Merger Sub, Inc., a Delaware corporation and wholly owned Subsidiary of the
      Company (“Merger Sub”), and Celgene Corporation, a Delaware corporation (“Celgene”);

     

    WHEREAS, pursuant to the Merger Agreement, Merger Sub will merge with and into Celgene (the “Merger”),

      with Celgene being the surviving corporation in the Merger and becoming a wholly-owned Subsidiary of the Company;

     

    WHEREAS, the CVRs shall be issued in accordance with and pursuant to the terms of the Merger Agreement; and

     

    WHEREAS, a registration statement on Form S-4 (No. 333-229464) with respect to the CVRs has been prepared and filed by the Company with the Commission
      (as defined below) and has become effective in accordance with the Securities Act of 1933, as amended.

     

    NOW, THEREFORE, in consideration of the foregoing premises and the consummation of the transactions contemplated by the Merger Agreement, it is
      covenanted and agreed, for the equal and proportionate benefit of all Holders of the Securities, as follows:

     

    ARTICLE 1

      DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

     

    Section 1.1          Definitions.  For all purposes of this CVR Agreement, except as otherwise expressly provided or unless the context otherwise requires:

     

    (a)          the terms defined in this Article 1 have the meanings assigned to them in this Article 1, and include the plural as well as the singular;

     

    (b)         all

          capitalized terms used in this CVR Agreement without definition shall have the respective meanings ascribed to them in the Merger Agreement;

     

    (c)        all
          other terms used herein which are defined in the Trust Indenture Act (as defined herein), either directly or by reference therein, have the respective meanings assigned to them therein;

     

    
      1

      
        

    

    
    (d)          the words “herein,” “hereof” and “hereunder” and other
          words of similar import refer to this CVR Agreement as a whole and not to any particular Article, Section or other subdivision; and

     

    (e)          whenever the words “include”, “includes” or “including”
          are used in this CVR Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.

     

    “Affiliate” of any specified Person means any other Person directly or indirectly
      controlling or controlled by or under direct or indirect common control with such specified Person.  For the purposes of this definition, “control” when used with respect to any specified Person means the power to direct the
      management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings
      correlative to the foregoing.

     

    “Aggregate Milestone Payment” shall have the meaning set forth in Section 3.1(c) of this CVR Agreement.

     

    “Applicable Procedures” means, with respect to any transfer or exchange of or for
      beneficial interests in any Global Security, the rules and procedures of the Depositary that apply to such transfer or exchange.

     

    “BB2121” means a chimeric antigen receptor (“CAR”)

      T cell therapy targeting B-cell maturation antigen (BCMA).

     

    “BB2121 Milestone” means the first approval by the FDA of a biologic license application
      (BLA) that grants Celgene, the Company or any of their respective Affiliates (or their respective successors and assigns) the right to commercially manufacture, market and sell BB2121 in the United States in accordance with applicable Law for the
      treatment of relapsed/refractory multiple myeloma in humans.

     

    “BB2121 Milestone Target Date” means March 31, 2021.

     

    “Board of Directors” means the board of directors of the Company or any other body
      performing similar functions, or any duly authorized committee of that board.

     

    “Board Resolution” means a copy of a resolution certified by the chairman of the Board of
      Directors, the chief executive officer, the secretary or any assistant secretary of the Company, to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Trustee.

     

    “Business Day” means any day (other than a Saturday or a Sunday) on which banking
      institutions in The City of New York, New York or any city in which the Corporate Trust Office of the Trustee is located are not authorized or obligated by Law or executive order to close and, if the CVRs are listed on a national securities exchange,
      electronic trading network or other suitable trading platform, such exchange, electronic network or other trading platform is open for trading.

     

    “Celgene” shall have the meaning set forth in the Recitals of this CVR Agreement.

     

    
      2

      
        

    

    “Code” means the U.S. Internal Revenue Code of 1986, as amended.

     

    “Commission” means the Securities and Exchange Commission, as from time to time
      constituted, created under the Exchange Act (as defined herein), or if at any time after the execution of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust Indenture Act, then the body
      performing such duties at such time.

     

    “Common Stock” shall have the meaning set forth in the Recitals of this CVR Agreement.

     

    “Company” means the Person (as defined herein) named as the “Company”
      in the first paragraph of this CVR Agreement, until a successor Person shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Company” shall mean such successor Person.  To the extent
      necessary to comply with the requirements of the provisions of Trust Indenture Act Sections 310 through 317, inclusive, to the extent that they are applicable to the Company, the term “Company” shall include any other obligor
      with respect to the Securities for the purposes of complying with such provisions.

     

    “Company Request” or “Company Order”
      mean, respectively, a written request or order signed in the name of the Company by the chairman of the Board of Directors, the chief executive officer, any President or Vice President, the secretary or any assistant secretary or any other individual
      duly authorized to act on behalf of the Company for such purpose or for any general purpose, and delivered to the Trustee.

     

    “Confidential Information” shall have the meaning set forth in Section 7.9 of this CVR Agreement.

     

    “Corporate Trust Office” means the office of the Trustee at which at any particular time
      its corporate trust business shall be principally administered, which office at the date of execution of this CVR Agreement is located at 1110 Centre Pointe Curve, Suite 101 Mendota Heights, Minnesota 55120-4101 or such other address as the Trustee
      may designate from time to time by notice to the Company.

     

    “CVRs” shall have the meaning set forth in the Preamble of this CVR Agreement.

     

    “CVR Agreement” means this instrument as originally executed and as it may from time to
      time be supplemented or amended pursuant to the applicable provisions hereof.

     

    “Default Interest Rate” means a rate equal to the sum of three percent (3%) plus the prime
      rate of interest quoted in the Money Rates section of The Wall Street Journal (New York Edition), or similar reputable data source,
      calculated daily on the basis of a three hundred sixty-five (365) day year or, if lower, the highest rate permitted under applicable Law.

     

    “Depositary” shall have the meaning set forth in Section 3.2 of this CVR Agreement.

     

    
      3

      
        

    

    “Diligent Efforts” means, with respect to any Product, efforts of a Person to carry out
      its obligations in a diligent manner using such effort and employing such resources normally used by such Person in the exercise of its reasonable business discretion relating to the research, development or commercialization of a product, that is of
      similar market potential at a similar stage in its development or product life, taking into account issues of market exclusivity (including patent coverage, regulatory and other exclusivity), safety and efficacy, product profile (including
      tolerability and convenience), the competitiveness of alternate products in the marketplace or under development, the launch or sales of one or more generic or biosimilar products,
        actual or likely pricing/reimbursement for the product, the likely timing of the product’s entry into the market, the likelihood of regulatory approval of the product and
        applicable labeling, and the profitability of the applicable product, and other relevant factors, including technical, commercial, legal, scientific, and/or medical factors, based on conditions then prevailing.

     

    “Direct Registration Securities” means Securities, the ownership of which is recorded on
      the Direct Registration System.  The terms “deliver,” “execute,” “issue,” “register,” “surrender,” “transfer” or “cancel,” when used with respect to Direct Registration Securities, shall refer to an entry or entries or an electronic transfer or transfers in the Direct Registration System.

     

    “Direct Registration System” means the system for the uncertificated registration of
      ownership of securities established by the Security Registrar and utilized by the Security Registrar pursuant to which the Security Registrar may record the ownership of CVRs without the issuance of a certificate, which ownership shall be evidenced
      by periodic statements issued by the Security Registrar to the Holders entitled thereto.

     

    “Event of Default” shall have the meaning set forth in Section 8.1 of this CVR Agreement.

     

    “Exchange Act” means the Securities Exchange Act of 1934, as amended.

     

    “Exchange Act Documents” shall have the meaning set forth in Section 5.4(a) of this CVR Agreement.

     

    “FDA” means the United States Food and Drug Administration or any successor agency.

     

    “Global Securities” means one or more securities in registered form, substantially in the
      form set forth in Annex A, and held by, or on behalf of, a Depositary.

     

    “Governmental Entity” means any domestic (federal or state), or foreign court, commission,
      governmental body, regulatory or administrative agency or other political subdivision thereof.

     

    “Holder” means a Person in whose name a Security is
      registered in the Security Register.

     

    “Indirect Participant” means a Person who holds a beneficial interest in a Global Security
      through a Participant.

     

    “Initial Milestone Target Date” means December 31, 2020.

     

    “JCAR017” means a CAR T cell therapy targeting CD-19.

     

    “JCAR017 Milestone” means the first approval by the FDA of a biologic license application
      (BLA) that grants Celgene, the Company or any of their respective Affiliates (or their respective successors and assigns) the right to commercially manufacture, market and sell JCAR017 in the United States in accordance with applicable Law for the
      treatment of any relapsed-refractory diffuse large B cell lymphoma in humans.

     

    
      4

      
        

    

    “Junior Obligations” has the meaning set forth in Section 10.1.

     

    “Law” means any foreign, federal, state, local or municipal laws, rules, judgments orders,
      regulations, statutes, ordinances, codes, decisions, injunctions, orders, decrees or requirements of any Governmental Entity.

     

    “Majority Holders” means, at the time of determination, Holders of at least a majority of the
      Outstanding CVRs.

     

    “Merger” shall have the meaning set forth in the Recitals of this CVR Agreement.

     

    “Merger Agreement” shall have the meaning set forth in the Recitals of this CVR Agreement.

     

    “Merger Sub” shall have the meaning set forth in the Recitals of this CVR Agreement.

     

    “Milestone” means the satisfaction of all (but not less than all) of the following: (i)
      the BB2121 Milestone has occurred on or prior to the BB2121 Milestone Target Date; (ii) the JCAR017 Milestone has occurred on or prior to the Initial Milestone Target Date; and (iii) the Ozanimod Milestone has occurred on or prior to the Initial
      Milestone Target Date.

     

    “Milestone Payment” means nine dollars ($9.00) per CVR.

     

    “Milestone Payment Date” means, with respect to the Milestone, the date that is selected
      by the Company that is no later twenty (20) Business Days following the first date on which the Milestone is achieved.

     

    “Milestone Payment Record Date” shall have the meaning set forth in Section 3.1(c) of this CVR Agreement.

     

    “Officer’s Certificate” when used with respect to the Company means a certificate signed
      by the chairman of the Board of Directors, the chief executive officer, any President or Vice President, the secretary or any assistant secretary or any other individual authorized to act on behalf of the Company, and delivered to the Trustee.

     

    “Opinion of Counsel” means a written opinion of counsel, who may be counsel for the Company.

     

    “Outstanding” when used with respect to Securities means, as of the date of determination,
      all Securities theretofore authenticated, as applicable, and delivered under this CVR Agreement, except: (i) Securities theretofore cancelled by the Trustee or delivered to the Trustee for cancellation and (ii) Securities in exchange for or in lieu
      of which other Securities have been authenticated, as applicable, and delivered pursuant to this CVR Agreement, other than any such Securities in respect of which there shall have been presented to the Trustee proof satisfactory to it that such
      Securities are held by a bona fide purchaser in whose hands the Securities are valid obligations of the Company; provided, however,
      that in determining whether the Holders of the requisite Outstanding Securities have given any request, demand, direction, consent or waiver hereunder, Securities owned by the Company or any
      Affiliate of the Company, whether held as treasury securities or otherwise, shall be disregarded and deemed not to be Outstanding.

     

    
      5

      
        

    

    “Ozanimod” means a small molecule sphingosine 1-phosphate receptor modulator, which binds
      to sphingosine 1-phosphate receptors 1 and 5.

     

    “Ozanimod Milestone” means the first approval by the FDA of a new drug application (NDA)
      that grants Celgene, the Company or any of their respective Affiliates (or their respective successors and assigns) the right to commercially manufacture, market and sell Ozanimod in the United States in accordance with applicable Law for the
      treatment of relapsing multiple sclerosis in humans.

     

    “Participant” means, with respect to the Depositary, a Person who has an account with the
      Depositary.

     

    “Party” shall mean the Trustee, the Company and/or Holder(s), as applicable.

     

    “Paying Agent” means any Person authorized by the Company to pay the amount determined
      pursuant to Section 3.1, if any, on any Securities on behalf of the Company.

     

    “Person” means any individual, corporation, partnership, joint venture, association,
      joint-stock company, trust, limited liability company, unincorporated organization or Governmental Entity.

     

    “President” when used with respect to the Company, means any president, whether or not
      designated by a number or a word or words added before or after the title of “president.”

     

    “Products” means each of (a) BB2121, (b) JCAR017 and (c) Ozanimod.

     

    “Representatives” shall have the meaning set forth in Section 7.9 of this CVR Agreement.

     

    “Responsible Officer” when used with respect to the Trustee means any officer assigned to
      the Corporate Trust Office who shall have direct responsibility for the administration of this CVR Agreement or any other officer of the Trustee to whom any corporate trust matter is referred because of such Person’s knowledge of and familiarity with
      the particular subject.

     

    “Securities” shall have the meaning set forth in the Preamble of this CVR Agreement.

     

    “Security Register” shall have the meaning set forth in Section 3.5(a) of this CVR Agreement.

     

    “Security Registrar” shall have the meaning set forth in Section 3.5(a) of this CVR Agreement.

     

    
      6

      
        

    

    “Senior Obligations” means any existing or
      future obligations of the Company, including the principal of, premium (if any), interest (including any interest accruing subsequent to the filing of a petition of bankruptcy at the rate provided for in the documentation with respect thereto,
      whether or not such interest is an allowed claim under applicable Law) on, and all other amounts owing thereon, (i) with respect to borrowed money, (ii) evidenced by notes, debentures, bonds or other similar debt instruments, (iii) with respect to
      the net obligations owed under interest rate swaps or similar agreements or currency exchange transactions, (iv) reimbursement obligations in respect of letters of credit and similar obligations, (v) in respect of capital leases, or (vi) guarantees
      in respect of obligations referred to in clauses (i) through (v) above; unless, in any case, the instrument creating or evidencing the same or pursuant to which the same is outstanding provides that such obligations are pari passu to or subordinate
      in right of payment to the Securities.

     

    Notwithstanding the foregoing, “Senior Obligations” shall not include:

     

    
      
        	

              	(A)	
                Junior Obligations;

              

      

    

     

    
      
        	

              	(B)	
                trade debt incurred in the ordinary course of business;

              

      

    

     

    
      
        	

              	(C)	
                any intercompany indebtedness between the Company and any of its Subsidiaries or Affiliates;

              

      

    

     

    
      
        	

              	(D)	
                indebtedness of the Company that is expressly subordinated in right of payment to Senior Obligations;

              

      

    

     

    
      
        	

              	(E)	
                indebtedness or other obligations of the Company that by its terms ranks equal or junior in right of payment to the Junior Obligations;

              

      

    

     

    
      
        	

              	(F)	
                indebtedness of the Company that, by operation of Law, is subordinate to any general unsecured obligations of the Company; or

              

      

    

     

    
      
        	

              	(G)	
                indebtedness evidenced by any guarantee of indebtedness ranking equal or junior in right of payment to the Junior Obligations.

              

      

    

     

    “Subsidiary” means, with respect to any Person, any corporation, limited liability
      company, association, partnership or other business entity of which more than fifty percent (50%) of the total voting power of shares of Voting Securities is at the time owned or controlled, directly or indirectly, by: (i) such Person; (ii) such
      Person and one or more Subsidiaries of such Person; or (iii) one or more Subsidiaries of such Person.

     

    “Tax” means any federal, state, local or foreign income, profits, gross receipts, license,
      payroll, employment, severance, stamp, occupation, premium, windfall profits, environmental, customs duty, capital stock, franchise, sales, social security, unemployment, disability, use, property, withholding, excise, transfer, registration,
      production, value added, alternative minimum, occupancy, estimated or any other tax of any kind whatsoever, together with any interest, penalty or addition thereto, imposed by any Governmental Entity responsible for the imposition of any such tax,
      whether disputed or not.

     

    “Tax Return” means any return, report, declaration, claim or other statement (including
      attached schedules) relating to Taxes.

     

    
      7

      
        

    

    “Termination Date” shall have the meaning set forth in Section 1.16 of this CVR Agreement.

     

    “Trust Indenture Act” means the Trust Indenture Act of 1939, as amended from time to time.

     

    “Trustee” means the Person named as the “Trustee” in the first
      paragraph of this CVR Agreement, until a successor Trustee shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Trustee” shall mean such successor Trustee.

     

    “Vice President” when used with respect to the Company, means any vice president, whether
      or not designated by a number or a word or words added before or after the title of “vice president.”

     

    “Voting Securities” means securities or other interests having voting power, or the right,
      to elect or appoint a majority of the directors, or any Persons performing similar functions, irrespective of whether or not stock or other interests of any other class or classes shall have or might have voting power or any right by reason of the
      happening of any contingency.

     

    Section 1.2          Compliance and Opinions.

     

    (a)         Upon

          any application or request by the Company to the Trustee to take any action under any provision of this CVR Agreement, the Company shall furnish to the Trustee an Officers’ Certificate stating that, in the opinion of the signor, all conditions
          precedent, if any, provided for in this CVR Agreement relating to the proposed action have been complied with and an Opinion of Counsel stating, subject to customary exceptions, that in the opinion of such counsel all such conditions precedent,
          if any, have been complied with, except that, in the case of any such application or request as to which the furnishing of such documents is specifically required by any provision of this CVR Agreement relating to such particular application or
          request, no additional certificate or opinion need be furnished.

     

    (b)         Every

          certificate or opinion with respect to compliance with a condition or covenant provided for in this CVR Agreement shall include: (i) a statement that each individual signing such certificate or opinion has read such covenant or condition and the
          definitions herein relating thereto; (ii) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; (iii) a statement that, in the
          opinion of each such individual, he or she has made such examination or investigation as is necessary to enable him or her to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv) a statement
          as to whether, in the opinion of each such individual, such condition or covenant has been complied with.

     

    Section 1.3           Form of Documents Delivered to Trustee.

     

    (a)         In

          any case where several matters are required to be certified by, or covered by an opinion of, any specified Person, it is not necessary that all such matters be certified by, or covered by the opinion of, only one such Person, or that they be so
          certified or covered by only one document, but one such Person may certify or give an opinion with respect to some matters and one or more other such Persons as to other matters, and any such Person may certify or give an opinion as to such
          matters in one or several documents.

     

    
      8

      
        

    

    (b)         Any

          certificate or opinion of an officer of the Company may be based, insofar as it relates to legal matters, upon a certificate or opinion of, or representations by, counsel.  Any such certificate or Opinion of Counsel may be based, insofar as it
          relates to factual matters, upon a certificate or opinion of, or representations by, an officer or officers of the Company stating that the information with respect to such factual matters is in the possession of the Company.

     

    (c)         Any

          certificate, statement or opinion of an officer of the Company or of counsel may be based, insofar as it relates to accounting matters, upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of
          the Company.  Any certificate or opinion of any independent firm of public accountants filed with the Trustee shall contain a statement that such firm is independent.

     

    (d)         Where

          any Person is required to make, give or execute two or more applications, requests, consents, certificates, statements, opinions or other instruments under this CVR Agreement, they may, but need not, be consolidated and form one instrument.

     

    Section 1.4          Acts of Holders.

     

    (a)         Any

          request, demand, authorization, direction, notice, consent, waiver or other action provided by this CVR Agreement to be given or taken by Holders may be embodied in and evidenced by one or more instruments of substantially similar tenor signed by
          such Holders in person or by an agent duly appointed in writing; and, except as herein otherwise expressly provided, such action shall become effective when such instrument or instruments are delivered to the Trustee and, where it is hereby
          expressly required, to the Company.  Such instrument or instruments (and the action embodied therein and evidenced thereby) are herein sometimes referred to as the “Act” of the Holders
          signing such instrument or instruments.  Proof of execution of any such instrument or of a writing appointing any such agent shall be sufficient for any purpose of this CVR Agreement and (subject to Section

              4.1) conclusive in favor of the Trustee and the Company, if made in the manner provided in this Section 1.4.  The Company may set a record date for purposes of
          determining the identity of Holders entitled to vote or consent to any action by vote or consent authorized or permitted under this CVR Agreement.  If not previously set by the Company, (i) the record date for determining the Holders entitled to
          vote at a meeting of the Holders shall be the date preceding the date notice of such meeting is mailed to the Holders, or if notice is not given, on the day next preceding the day such meeting is held, and (ii) the record date for determining the
          Holders entitled to consent to any action in writing without a meeting shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Company.  If a record date is fixed, those
          Persons who were Holders of Securities at such record date (or their duly designated proxies), and only those Persons, shall be entitled to take such action by vote or consent or, except with respect to clause (d) below, to revoke any vote or
          consent previously given, whether or not such Persons continue to be Holders after such record date.  No such vote or consent shall be valid or effective for more than one hundred twenty (120) days after such record date.

     

    
      9

      
        

    

    (b)          The fact and date of the execution by any Person of any such instrument or writing may be proved in any reasonable manner which the Trustee deems sufficient.

     

    (c)          The ownership of Securities shall be proved by the Security Register.  Neither the Company nor the Trustee nor any agent of the Company or the Trustee shall be affected by any notice to the contrary.

     

    (d)         At

          any time prior to (but not after) the evidencing to the Trustee, as provided in this Section 1.4, of the taking of any action by the Holders of the Securities specified in this CVR
          Agreement in connection with such action, any Holder of a Security the serial number of which is shown by the evidence to be included among the serial numbers of the Securities the Holders of which have consented to such action may, by filing
          written notice at the Corporate Trust Office and upon proof of holding as provided in this Section 1.4, revoke such action

            so far as concerns such Security.  Any request, demand, authorization, direction, notice, consent, waiver or other action by the Holder of any Security shall bind every future Holder of the same Security or the Holder of every Security issued
            upon the registration of transfer thereof or in exchange therefor or in lieu thereof, in respect of anything done, suffered or omitted to be done by the Trustee, any Paying Agent or the Company in reliance thereon, whether or not notation of
            such action is made upon such Security.

     

    Section 1.5           Notices, etc., to Trustee and Company.  Any request, demand, authorization, direction, notice, consent, waiver or Act of Holders or other document
      provided or permitted by this CVR Agreement to be made upon, given or furnished to, or filed with:

     

    (a)          the Trustee by any Holder or by the Company shall be sufficient for every purpose hereunder if made, given, furnished or filed, in writing, to or with the Trustee at its Corporate Trust Office; or

     

    (b)          the Company by the Trustee or by any Holder shall be sufficient for every purpose hereunder if in writing and mailed, first-class postage prepaid, to the Company addressed to it at:

     

    Bristol-Myers Squibb Company

    430 E. 29th Street, 14th Floor

    New York, New York 10016

    Attn:  Executive Vice President, General Counsel

     

    with copies to (which shall not constitute notice):

     

    Bristol-Myers Squibb Company

    Route 206 & Province Line Road

    Princeton, New Jersey  08540

     

    
      10

      
        

    

    Attn:   Senior Vice President and Deputy General
          Counsel, Transactional Practice Group

     

    and

     

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    Attn:     David Fox, P.C.

     Daniel Wolf, P.C.

     Jonathan Davis, P.C.

     

    or at any other address previously furnished in writing to the Trustee by the Company.

     

    Section 1.6           Notice
          to Holders; Waiver.

     

    (a)         Where

          this CVR Agreement provides for notice to Holders of any event, such notice shall be sufficiently given (unless otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at
          the Holder’s address as it appears in the Security Register, not later than the latest date, and not earlier than the earliest date, prescribed for the giving of such notice.  In any case where notice to Holders is given by mail, neither the
          failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders.  Where this CVR Agreement provides for notice in any manner, such notice may
          be waived in writing by the Person entitled to receive such notice, either before or after the event, and such waiver shall be the equivalent of such notice.  Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not
          be a condition precedent to the validity of any action taken in reliance upon such waiver.

     

    (b)         In

          case by reason of the suspension of regular mail service or by reason of any other cause, it shall be impracticable to mail notice of any event as required by any provision of this CVR Agreement, then any method of giving such notice as shall be
          satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice.

     

    Section 1.7        
      Conflict with Trust Indenture Act.  If any provision hereof limits, qualifies or conflicts with another provision which is required or deemed to be included in this CVR Agreement by any of
      the provisions of the Trust Indenture Act, such required or deemed provision shall control.

     

    Section 1.8       
         Effect of Headings and Table of Contents.  The Article and Section headings herein and the Table of Contents are for convenience only and shall not affect the construction hereof.

     

    Section 1.9      
         Benefits of Agreement.  Nothing in this CVR Agreement or in the Securities, express or implied, shall give to any Person (other than the Parties hereto and their successors hereunder,
      any Paying Agent and the Holders) any benefit or any legal or equitable right, remedy or claim under this CVR Agreement or under any covenant or provision herein contained, all such covenants and provisions being for sole benefit of the Parties
      hereto and their successors, any Paying Agent and of the Holders.

     

    
      11

      
        

    

    Section 1.10     Governing Law.  THIS CVR AGREEMENT AND ALL SUITS, ACTIONS, PROCEEDINGS, CLAIMS AND CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) BASED UPON, ARISING OUT OF OR RELATING TO THIS CVR AGREEMENT,
      THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS CVR AGREEMENT OR THE SECURITIES, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK INCLUDING SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW
      WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF.  EACH OF THE COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT SITTING
      IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK OR ANY FEDERAL COURT SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN RESPECT OF ANY SUIT, ACTION, PROCEEDING, CLAIM OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT) BASED UPON,
      ARISING OUT OF OR RELATING TO THIS CVR AGREEMENT, THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS CVR AGREEMENT OR THE SECURITIES, AND IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE
      AFORESAID COURTS.  EACH OF THE COMPANY AND THE TRUSTEE AGREES THAT PROCESS MAY BE SERVED UPON THEM IN ANY MANNER AUTHORIZED BY THE LAWS OF THE STATE OF NEW YORK FOR SUCH PERSONS AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO
      UNDER APPLICABLE LAW, ANY OBJECTION IT MAY NOW OR HEREAFTER HAVE TO SUCH SERVICE OF PROCESS, THE LAYING OF THE VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT AND ANY CLAIM THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN
      ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

     

    Section 1.11    
          Legal Holidays.  In the event that the Milestone Payment Date shall not be a Business Day, then (notwithstanding any provision of this CVR Agreement or the Securities to the contrary)
      payment on the Securities need not be made on such date, but may be made, without the accrual of any interest thereon, on the next succeeding Business Day with the same force and effect as if made on the Milestone Payment Date.

     

    Section 1.12      
        Separability Clause.  In case any provision in this CVR Agreement or in the CVRs shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
      provisions shall not in any way be affected or impaired thereby.

     

    Section 1.13       
      No Recourse Against Others.  A director, officer, employee, agent or representative of the Company or any Affiliate of the Company or the Trustee shall not have any liability for any
      obligations of the Company or the Trustee under the Securities or this CVR Agreement or for any claim based on, in respect of or by reason of such obligations or their creation.  By
        accepting a Security each Holder waives and releases all such liability and all such claims.  The waiver and release are part of the consideration for the issue of the Securities.

     

    
      12

      
        

    

    Section 1.14     
         Counterparts.  This CVR Agreement shall be signed in any number of counterparts with the same effect as if the signatures to each counterpart were upon a single instrument, and all such
      counterparts together shall be deemed an original of this CVR Agreement.

     

    Section 1.15       
      Acceptance of Trust.  Equiniti Trust Company, a limited trust company organized under the laws of the state of New York, the Trustee named herein, hereby accepts the trusts in this CVR
      Agreement declared and provided, upon the terms and conditions set forth herein.

     

    Section 1.16   
           Termination.  This CVR Agreement will, automatically and without any further action of any Party, terminate and be of no force or effect, and the Parties hereto shall have no liability
      or obligations hereunder, at the following time (the “Termination Date”): (a) if as of the end of the day on the Initial Milestone Target Date, either the JCAR017 Milestone or the Ozanimod
      Milestone has not occurred, 12:01 a.m. New York City time on the calendar day following the Initial Milestone Target Date, (b) if both the JCAR017 Milestone and the Ozanimod Milestone have occurred on or prior to the Initial Milestone Target Date
      but, as of the end of the day on the BB2121 Milestone Target Date, the BB2121 Milestone has not occurred, 12:01 a.m. New York City time on the calendar day following the BB2121 Milestone Target Date or (c) if the Milestone has been achieved, the
      calendar day following the date on which the Trustee has paid the Milestone Payment to the Holders in accordance with Section 3.1(c); provided,
      however, that (A) Sections 1.5, 1.6, 1.7, 1.8, 1.9, 1.10, 1.12, 1.13, 4.7, 7.5,
      7.9, 7.10, Article 8, this Section 1.16 and Section 1.1 (to the extent related to the foregoing) shall survive termination of this CVR Agreement in accordance with their terms; and (B) the termination of this CVR Agreement shall not relieve any Party of any liability arising from any material breach of its obligations under this CVR Agreement occurring prior to the Termination Date. The Company shall
      provide the Trustee and Paying Agent written notice (email being sufficient) of the non-occurrence of the Milestone as promptly as practicable thereafter and, if the Milestone has not occurred prior to the BB2121 Milestone Target Date, at least seven
      (7) Business Days following the BB2121 Milestone Target Date (unless the Trustee consents to a shorter notice period).

     

    ARTICLE 2

      SECURITY FORMS

     

    Section 2.1       
         Forms Generally.

     

    (a)         (i) The

          Global Securities and the Trustee’s certificate of authentication shall be in substantially the forms set forth in Annex A, attached hereto and incorporated herein by this reference,
          with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this CVR Agreement and may have such letters, numbers or other marks of identification and such legends or endorsements placed thereon
          as may be required to comply with the rules of any securities exchange or as may be required by Law or any rule or regulation pursuant thereto, all as may be determined by the officers executing such Global Securities, as evidenced by their
          execution of the Global Securities.  Any portion of the text of any Global Security may be set forth on the reverse thereof, with an appropriate reference thereto on the face of the Global Security.

     

    
      13

      
        

    

    (ii)        The Global Securities shall be typewritten, printed, lithographed or engraved on
          steel engraved borders or produced by any combination of these methods or may be produced in any other manner permitted by the rules of any securities exchange on which the Securities may be listed, all as determined by the officers executing
          such Global Securities, as evidenced by their execution of such Global Securities.

     

    (b)          The Direct Registration Securities shall be uncertificated and shall be evidenced by the Direct Registration System maintained by the Security Registrar.

     

    ARTICLE 3

      THE SECURITIES

     

    Section 3.1           Title and Terms.

     

    (a)         The

          aggregate number of CVRs which may be authenticated, as applicable, and delivered under this CVR Agreement is limited to a number equal to [_____], except for Securities authenticated, as applicable, and delivered upon registration of transfer
          of, or in exchange for, or in lieu of, other Securities pursuant to Section 3.5, 3.6 or 6.6.  From and after the Merger

            Effective Time, the Company shall not be permitted to issue any CVRs that have the right to receive any portion of the Milestone Payment, except as provided and in accordance with the terms and conditions of the Merger Agreement.

     

    (b)         The

          Securities shall be known and designated as the “Series B Contingent Value Rights” of the Company.

     

    (c)         If

        the Milestone is achieved, then, on or prior to the Milestone Payment Date, the Company shall pay, or cause to be paid, to the Trustee, by wire transfer to the account designated in writing by the Trustee, an amount equal to the product of (A) the
        Milestone Payment, multiplied by (B) the number of Securities Outstanding as of such time (the “Aggregate Milestone Payment”), and the Trustee shall promptly (and in any event within two (2) Business Days of the receipt of the Aggregate Milestone Payment from the Company) pay to each Holder of record of the Securities
        as of 5:00 p.m. New York City time, three (3) Business Days prior to the Milestone Payment Date (the “Milestone Payment Record Date”) an amount equal to the product of (x) the Milestone
        Payment, multiplied by (y) the number of Securities held of record by such Holder as of the Milestone Payment Record Date.  Subject to Section

            1.16, the Company’s obligations to pay the Milestone Payment shall terminate in its entirety on the Termination Date. If the Milestone is achieved, the Company shall notify the Trustee and Paying Agent of the Milestone Payment Date
        in writing (email being sufficient) at least ten (10) Business Days prior to the Milestone Payment Date (unless the Trustee consents to a shorter notice period).  Such notice shall be accompanied by an Officer’s Certificate which sets forth, in
        reasonable detail, the calculation of the Aggregate Milestone Payment to be made to the Holders.

     

    (d)          The Holders of the CVRs, by acceptance thereof, agree that no joint venture, partnership or other fiduciary relationship is created hereby or by the Securities.

     

    
      14

      
        

    

    (e)          Other than in the case of interest on amounts due and payable after the occurrence of an Event of Default, no interest or dividends shall accrue on any amounts payable in respect of the CVRs.

     

    (f)          The Parties hereto agree to treat the CVRs for all Tax purposes as additional consideration for the shares of Common Stock, the Company Stock Options, the Company RSU Awards, the Company PSU Awards and Company RSAs, as applicable, pursuant to the Merger Agreement, and none of the Parties hereto will take any
          position to the contrary on any Tax Return or for other Tax purposes except as otherwise required by applicable Law.  The Company shall report imputed interest on the CVRs pursuant to Section 483 of the Code, except as otherwise required by
          applicable Law.

     

    (g)         The

          CVRs and any interest thereon may be sold, assigned, pledged encumbered or in any manner transferred or disposed of, in whole or in part, only in compliance with applicable United States federal and state securities Laws and, to the extent
          applicable, in accordance with Section 3.5.

     

    (h)         The

          Holder of any CVR is not, and shall not, by virtue thereof, be entitled to any rights of a holder of any Voting Securities or other equity security or other ownership interest of the Company, in any constituent company to the Merger or in any of
          their respective Affiliates, either at Law or in equity, and the rights of the Holders are limited to those contractual rights expressed in this CVR Agreement.

     

    (i)          Except as provided in this CVR Agreement, none of the Company or any of its Affiliates shall have any right to set-off any amounts owed or claimed to be owed by any Holder to any of them against such Holder’s Securities or the Milestone
          Payment or other amount payable to such Holder in respect of such Securities.

     

    Section 3.2         Registrable Form.  The Securities shall be issuable only in registered form.  The CVRs shall be issued initially in the form of (a) one or more permanent
      Global Securities, deposited with the Trustee, as the custodian for The Depository Trust Company, its nominees and successors (the “Depositary”), or (b) one or more Direct Registration
      Securities.  Each Global Security will represent such of the outstanding CVRs as will be specified therein and each shall provide that it represents the aggregate number of outstanding CVRs from time to time endorsed thereon and that the aggregate
      number of outstanding CVRs represented thereby may from time to time be reduced or increased, as appropriate, to reflect exchanges and/or issuances as provided and in accordance with the terms and conditions of the Merger Agreement.

     

    Section 3.3        
        Execution, Authentication, Delivery and Dating.

     

    (a)         The

          Global Securities shall be executed on behalf of the Company by its chairman of the Board of Directors, its chief executive officer, any President or Vice President or any other individual duly authorized to act on behalf of the Company for such
          purpose or any general purpose, but need not be attested.  The signature of any of these individuals on the Global Securities may be manual or facsimile.

     

    
      15

      
        

    

    (b)         Global

          Securities bearing the manual or facsimile signatures of individuals who were, at the time of execution, the proper officers of the Company shall bind the Company, notwithstanding that such individuals or any of them have ceased to hold such
          offices prior to the authentication and delivery of such Global Securities or did not hold such offices at the date of such Global Securities.

     

    (c)         At

          any time and from time to time after the execution and delivery of this CVR Agreement, the Company may deliver a Company Order for the authentication, as applicable, and delivery of Securities, and the Trustee, in accordance with such Company
          Order, shall authenticate, as applicable, and deliver such Securities as provided in this CVR Agreement and not otherwise.  In the case of Global Securities, such Company Order shall be accompanied by Global Securities executed by the Company and
          delivered to the Trustee for authentication in accordance with such Company Order.

     

    (d)          Each Global Security shall be dated the date of its authentication.

     

    (e)         No

          Global Security shall be entitled to any benefit under this CVR Agreement or be valid or obligatory for any purpose unless there appears on such Security a certificate of authentication substantially in the form provided for herein duly executed
          by the Trustee, by manual or facsimile signature of an authorized officer, and such certificate upon any Security shall be conclusive evidence, and the only evidence, that such Global Security has been duly authenticated and delivered hereunder
          and that the Holder is entitled to the benefits of this CVR Agreement.

     

    (f)          Direct

          Registration Securities need not be authenticated, and shall be valid and obligatory for all purposes and shall entitle each Holder thereof to all benefits of this CVR Agreement.

     

    Section 3.4        
        [Intentionally Omitted].

     

    Section 3.5           Registration, Registration of Transfer and Exchange.

     

    (a)         The

        Company shall cause to be kept at the office of the Trustee a register (the register maintained in such office and in any other office or agency designated pursuant to Section 7.2 being
        herein sometimes referred to as the “Security Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of Securities
        and of transfers of Securities.  The Trustee is hereby initially appointed “Security Registrar” for the purpose of registering Securities and transfers of Securities as herein provided.

     

    
      16

      
        

    

    (b)         (i)

          A Global Security may not be transferred except as a whole by the Depositary to a nominee of the Depositary, by a nominee of the Depositary to the Depositary or to another nominee of the Depositary, or by the Depositary or any such nominee to a
          successor Depositary or a nominee of such successor Depositary.  All Global Securities will be exchanged by the Company for Direct Registration Securities if (1) the Company delivers to the Security Registrar notice from the Depositary that it is
          unwilling or unable to continue to act as Depositary or that it is no longer a clearing agency registered under the Exchange Act and, in either case, a successor Depositary is not appointed by the Company within 120 days after the date of such
          notice from the Depositary, (2) the Company in its sole discretion determines that the Global Securities (in whole but not in part) should be exchanged for Direct Registration Securities and delivers a written notice to such effect to the
          Security Registrar or (3) an Event of Default has occurred and is continuing and the Security Registrar has received a request from the Depositary to issue Direct Registration Securities.  Upon the occurrence of either of the preceding events in
          (1) or (2) above, Direct Registration Securities shall be issued in such names as the Depositary shall instruct the Trustee.  Global Securities also may be exchanged or replaced, in whole or in part, as provided in Section 3.6 hereof.  Every Global Security authenticated and delivered in exchange for, or in lieu of, a Global Security or any portion thereof, pursuant to this Sections

              3.5 or 3.6 hereof, shall be authenticated and delivered in the form of, and shall be, a Global Security.  A Global Security may not be exchanged for another Global
          Security other than as provided in this Section 3.5(b)(i), however, beneficial interests in a Global Security may be transferred and exchanged as provided in Section 3.5(b)(ii) or (iii) hereof.

     

    (ii)         The transfer and exchange of beneficial interests in the Global Securities will be
          effected through the Depositary, in accordance with the provisions of this CVR Agreement and the Applicable Procedures.  Beneficial interests in any Global Security may be
            transferred to Persons who take delivery thereof in the form of a beneficial interest in Global Security.  No written orders or instructions shall be required to be delivered to the Security Registrar to effect the transfers described in this Section 3.5(b)(ii).

     

    (iii)       If any holder of a beneficial interest in a Global Security proposes to exchange
          such beneficial interest for a Direct Registration Security or to transfer such beneficial interest to a Person who takes delivery thereof in the form of a Direct Registration Security, then the Security Registrar will cause the aggregate number
          of CVRs represented by the applicable Global Security to be reduced accordingly pursuant to Section 3.5(b)(vi) hereof, and the Security Registrar will deliver to the Person designated
          in the instructions a Direct Registration Security in the appropriate number of CVRs.  Any Direct Registration Security issued in exchange for a beneficial interest pursuant to this Section
              3.5(b)(iii) will be registered in such name or names and in such authorized denomination or denominations as the holder of such beneficial interest requests through instructions to the Security Registrar from or through the
          Depositary and the Participant or Indirect Participant.

     

    (iv)       A Holder of a Direct Registration Security may exchange such Direct Registration
          Security for a beneficial interest in a Global Security or transfer such Direct Registration Security to a Person who takes delivery thereof in the form of a beneficial interest in a Global Security at any time.  Upon receipt of a request for
          such an exchange or transfer together with, in case of a transfer, a duly endorsed or properly executed instrument of transfer in form reasonably satisfactory to the Company and the Security Registrar duly executed by the Holder (or by his or her
          attorney duly authorized in writing and with appropriate evidence of authority), the Security Registrar will cancel the applicable Direct Registration Security and increase or cause to be increased the aggregate number of CVRs represented by one
          of the Global Securities.

     

    
      17

      
        

    

    (v)        Upon

          request by a Holder of Direct Registration Securities and such Holder’s compliance with the provisions of this Section 3.5(b)(v), the Security Registrar will register the transfer or
          exchange of Direct Registration Securities.  Prior to such registration of transfer or exchange, the requesting Holder must present to the Security Registrar a written instruction of transfer in form satisfactory to the Company and the Security
          Registrar duly executed by such Holder (or by his or her attorney, duly authorized in writing and with appropriate evidence of authority), together with a duly endorsed or properly executed instrument of transfer.  A Holder of Direct Registration
          Securities may transfer such Direct Registration Securities to a Person who takes delivery thereof in the form of Direct Registration Securities.  Upon receipt of a request to register such a transfer, together with a properly executed instrument
          of transfer or endorsement and appropriate evidence of authority, which shall include a signature guarantee from an eligible guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association, and
          any other reasonable evidence of authority that may be required by the Security Registrar, the Security Registrar shall register the Direct Registration Securities pursuant to the instructions from the Holder thereof.

     

    (vi)       At such time as all beneficial interests in a particular Global Security have been
          exchanged for Direct Registration Securities or a particular Global Security has been repurchased or canceled in whole and not in part, each such Global Security will be returned to or retained and canceled by the Security Registrar in accordance
          with Section 3.9 hereof.  At any time prior to such cancellation, if any beneficial interest in a Global Security is exchanged for or transferred to a Person who will take delivery
          thereof in the form of a beneficial interest in another Global Security or for Direct Registration Securities, the aggregate number of CVRs represented by such Global Security will be reduced accordingly and an endorsement will be made on such
          Global Security by the Security Registrar or by the Depositary at the direction of the Security Registrar to reflect such reduction; and if the beneficial interest is being exchanged for or transferred to a Person who will take delivery thereof
          in the form of a beneficial interest in another Global Security, such other Global Security will be increased accordingly and an endorsement will be made on such Global Security
            by the Security Registrar or by the Depositary at the direction of the Security Registrar to reflect such increase.

     

    (vii)       (A) To permit registrations of transfers and exchanges, the Company will execute and
          the Trustee will authenticate Global Securities upon receipt of a Company Order in accordance with Section 3.3 hereof or at the Security Registrar’s request.

     

    (B)         No service charge will be made to a Holder of a beneficial interest in a Global Security or to a Holder of a Direct Registration Security for any registration of transfer or exchange, but the Company may require payment of a sum
          sufficient to cover any transfer tax or similar governmental charge payable in connection therewith.

     

      

    
      18

      
        

    

    (C)         All Global Securities and Direct Registration Securities issued upon any registration of transfer or exchange of Global Securities or Direct Registration Securities will be the valid obligations of the Company, evidencing the same
          rights, and entitled to the same benefits under this CVR Agreement, as the Global Securities or Direct Registration Securities surrendered upon such registration of transfer or exchange.

     

    (D)          The Trustee will authenticate Global Securities in accordance with the provisions of Section 3.3 hereof.

     

    Section 3.6      
          Mutilated, Destroyed, Lost and Stolen Securities.

     

    (a)          If (i) any mutilated Global Security is surrendered to the Trustee, or (ii) the Company and the Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Global Security, and there is delivered to the
          Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, then, in the absence of notice to the Company or the Trustee that such Global Security has been acquired by a bona fide purchaser, the
          Company shall execute and, upon delivery of a Company Order, the Trustee shall authenticate, as applicable, and deliver, in exchange for any such mutilated Global Security or in lieu of any such destroyed, lost or stolen Global Security, a new
          CVR, in the form of either a Global Security or a Direct Registration Security, of like tenor and amount of CVRs, bearing a number not contemporaneously outstanding.

     

    (b)        In

          case any such mutilated, destroyed, lost or stolen Global Security has become or is to become finally due and payable within fifteen (15) days, the Company in its discretion may, instead of issuing a new CVR, pay to the Holder of such Security on
          the Milestone Payment Date all amounts due and payable with respect thereto.

     

    (c)         Every

          new Security issued pursuant to this Section 3.6 in lieu of any destroyed, lost or stolen Global Security shall constitute an original additional contractual obligation of the Company,
          whether or not the destroyed, lost or stolen Global Security shall be at any time enforceable by anyone, and shall be entitled to all benefits of this CVR Agreement equally and proportionately with any and all other Securities duly issued
          hereunder.

     

    (d)          The provisions of this Section 3.6 are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of
          mutilated, destroyed, lost or stolen Global Securities.

     

    Section 3.7       
        Payments with Respect to CVRs.  Payment of any amounts pursuant to the CVRs shall be made in such coin or currency of the United States of America as at the time is legal tender for the
      payment of public and private debts.  The Company may, at its option, pay such amounts by wire transfer or check payable in such money.

     

    Section 3.8      
         Persons Deemed Owners.  The Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name any Security is registered as the owner of such Security
      for the purpose of receiving payment on such Security and for all other purposes whatsoever, whether or not such Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the
      contrary.

     

      

    
      19

      
        

    

    Section 3.9      
         Cancellation.  All Securities surrendered for payment, registration of transfer or exchange shall, if surrendered to any Person other than the Trustee, be delivered to the Trustee and
      shall be promptly canceled by it.  The Company may at any time deliver to the Trustee for cancellation any Global Securities previously authenticated and delivered hereunder which the Company may have acquired in any manner whatsoever, and all Global
      Securities so delivered shall be promptly canceled by the Trustee.  No Securities shall be authenticated in lieu of or in exchange for any Securities canceled as provided in this Section, except as expressly permitted by this CVR Agreement.  All
      cancelled Global Securities held by the Trustee shall be destroyed and a certificate of destruction shall be issued by the Trustee to the Company, unless otherwise directed by a Company Order.

     

    Section 3.10       
      CUSIP Numbers.  The Company in issuing the CVRs may use “CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP”
      numbers in notices to the Holders as a convenience to the Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the CVRs or as contained in any notices and that
      reliance may be placed only on the other identification numbers printed on the CVRs, and any such notice shall not be affected by any defect in or omission of such numbers.  The Company will promptly notify the Trustee of any change in the “CUSIP” numbers.

     

    ARTICLE 4

      THE TRUSTEE

     

    Section 4.1           Certain Duties and Responsibilities.

     

    (a)         The

          Trustee, prior to the occurrence of an Event of Default (as defined in Section 8.1) with respect to the Securities and after the curing or waiving of all Events of Default which may
          have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this CVR Agreement and no implied covenants shall be read into this CVR Agreement against the Trustee.  In case an Event of Default with
          respect to the Securities has occurred (which has not been cured or waived), the Trustee shall exercise such of the rights and powers vested in it by this CVR Agreement, and use the same degree of care and skill in their exercise, as a reasonably
          prudent person would exercise or use under the circumstances in the conduct of his or her own affairs.

     

    (b)         In

          the absence of bad faith on its part, prior to the occurrence of an Event of Default and after the curing or waiving of all such Events of Default which may have occurred, the Trustee may conclusively rely, as to the truth of the statements and
          the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee which conform to the requirements of this CVR Agreement; but in the case of any such certificates or opinions which by any provision hereof
          are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this CVR Agreement (but need not confirm or investigate the accuracy
          of mathematical calculations or the other facts stated therein).

     

    
      20

      
        

    

    (c)         No

          provision of this CVR Agreement shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that (i) this Subsection (c) shall not be construed to
          limit the effect of Subsections (a) and (b) of this Section 4.1; (ii) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it
          shall be proved that the Trustee was negligent in ascertaining the pertinent facts; and (iii) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the
          Holders pursuant to Section 8.9 relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred
          upon the Trustee, under this CVR Agreement; and (iv) no provision of this CVR Agreement shall require the Trustee to expend its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the
          exercise of any of its rights and powers, to the extent that the Trustee has reasonable grounds, after consultation with outside counsel, for believing that repayment of such funds or adequate indemnity against such liability is not reasonably
          assured to it.

     

    (d)         Whether

          or not therein expressly so provided, every provision of this CVR Agreement relating to the conduct or affecting the liability of or affording protection to the Trustee shall be subject to the provisions of this Section 4.1.

     

    Section 4.2       
         Certain Rights of Trustee.  Subject to the provisions of Section 4.1, including the duty of care that the Trustee is required
      to exercise upon the occurrence of an Event of Default:

     

    (a)          the Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence
          of indebtedness or other paper or document reasonably believed by it to be genuine and to have been signed or presented by the proper party or parties and the Trustee need not investigate any fact or matter stated in the document;

     

    (b)          any request or direction or order of the Company mentioned herein shall be sufficiently evidenced by a Company Request or Company Order and any resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution;

     

    (c)         whenever

          in the administration of this CVR Agreement the Trustee shall deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically
          prescribed) may, in the absence of bad faith on its part, rely upon an Officers’ Certificate or an Opinion of Counsel;

     

    (d)          the Trustee may consult with counsel and the written advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good
          faith and in accordance with such advice or Opinion of Counsel;

     

    
      21

      
        

    

    (e)          the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this CVR Agreement at the request or direction of any of the Holders pursuant to this CVR Agreement, unless such Holders shall have offered
          to the Trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction;

     

    (f)          the Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture,
          note, coupon, security, or other paper or document, but the Trustee in its discretion may make such further inquiry or investigation into such facts or matters as it may see fit, and if the Trustee shall determine to make such further inquiry or
          investigation, it shall be entitled to examine the pertinent books and records of the Company, personally or by agent or attorney, as may be reasonably necessary for such inquiry or investigation and in a manner so as to not unreasonably
          interfere with the normal business operations of the Company or any of its Affiliates; provided, however, that Company shall not be required to provide any books or records to the extent that the provision thereof (i) would, as reasonably determined based on the advice of outside counsel, jeopardize any attorney-client
          privilege or (ii) would contravene any Law or any contract or agreement to which the Company or any of its Affiliates is subject or bound;

     

    (g)         the

          Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or
          attorney appointed with due care by it hereunder;

     

    (h)          the Trustee shall not be liable for any action taken, suffered or omitted to be taken by it in good faith and reasonably believed by it to be authorized or within the discretion or rights or powers conferred upon it by this CVR
          Agreement; and

     

    (i)          the

          Trustee shall not be deemed to have notice of any default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice thereof has been received by such Responsible Officer at the offices
          of the Trustee and such notice references the CVRs and this CVR Agreement and the fact that such notice constitutes notification of default.

     

    (j)          Subject

          to Section 4.1, in no event shall the Trustee be responsible or liable for special, incidental, indirect, punitive or consequential loss or damage of any kind whatsoever (including, but
          not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action; and

     

    (k)         the

          rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and each
          Person employed by the Trustee to act hereunder.

     

    
      22

      
        

    

    Section 4.3          Notice of Default.  If a default occurs hereunder with respect to the Securities, the Trustee shall give the Holders notice of any such default actually known to it as and to the extent
      applicable and provided by the Trust Indenture Act; provided, however, that in the case of any default of the character
      specified in Section 8.1(b) with respect to the Securities, no notice to Holders shall be given until at least thirty (30) days after the occurrence thereof.  For the purpose of this Section 4.3, the term “default” means any event that is, or after notice or lapse of time or both would become, an Event of Default with respect to the Securities.

     

    Section 4.4          Not Responsible for Recitals or Issuance of Securities.  The Trustee shall not be accountable for the Company’s use of the Securities or the Merger Agreement.  The recitals contained herein and
      in the Securities, except the Trustee’s certificates of authentication, shall be taken as the statements of the Company, and the Trustee assumes no responsibility for their
        correctness.  The Trustee makes no representations as to the validity or sufficiency of this CVR Agreement or of the Securities or the Merger Agreement. The Trustee is not a party to, is not bound by, and has no duties or obligations under, the
        Merger Agreement unless specifically stated herein.

     

    Section 4.5          May Hold Securities.  The Trustee, any Paying Agent, Security Registrar or any other agent of the Company, in its individual or any other capacity, may become the owner or pledgee of Securities,
      and, subject to Sections 4.8 and 4.13, may otherwise deal with the Company with the same rights it would have if it were not
      Trustee, Paying Agent, Security Registrar or such other agent.

     

    Section 4.6        
      Money Held in Trust.  Money held by the Trustee in trust hereunder need not be segregated from other funds except to the extent required by Law. The Trustee shall be under no liability for
      interest on any money received by it hereunder, except as otherwise agreed by the Trustee in writing with the Company.

     

    Section 4.7          Compensation and Reimbursement.  The Company agrees:

     

    (a)          to pay to the Trustee from time to time reasonable compensation for all services rendered by it hereunder in such amount as the Company and the Trustee shall agree from time to time (which compensation shall not be limited by any
          provision of Law in regard to the compensation of a trustee of an express trust);

     

    (b)        except

          as otherwise expressly provided herein, to reimburse the Trustee upon its request for all reasonable and out-of-pocket expenses, disbursements and advances incurred or made by the Trustee in accordance with any provision of this CVR Agreement
          (including the reasonable compensation and the reasonable expenses and disbursements of its agents and counsel), except any such expense, disbursement or advance as may be attributable to the Trustee’s negligence, bad faith or willful misconduct;
          and

     

    
      23

      
        

    

    (c)          to indemnify the Trustee and each of its agents, officers, directors and employees (each an “indemnitee”) for, and to hold it harmless against, any loss,
          liability or reasonable and out-of-pocket expense (including reasonable and out-of-pocket attorneys’ fees and expenses) incurred without negligence, bad faith or willful misconduct on its part, arising out of or in connection with the acceptance
          or administration of this trust and the performance of its duties hereunder, including the reasonable and out-of-pocket costs and expenses of defending itself against any claim or liability in connection with the exercise or performance of any of
          its powers or duties hereunder.  The Company’s payment obligations pursuant to this Section 4.7 shall survive the termination of this CVR Agreement.  When the Trustee incurs reasonable
          and out-of-pocket expenses after the occurrence of an Event of Default specified in Section 8.1(c) or 8.1(d) with respect to
          the Company, the expenses will constitute expenses of administration under bankruptcy Laws.

     

    Section 4.8        
        Disqualification; Conflicting Interests.

     

    (a)          If applicable, to the extent that the Trustee or the Company determines that the Trustee has a conflicting interest within the meaning of the Trust Indenture Act, the Trustee shall immediately notify the Company of such conflict and,
          within ninety (90) days after ascertaining that it has such conflicting interest, either eliminate such conflicting interest or resign to the extent and in the manner provided by, and subject to the provisions of, the Trust Indenture Act and this
          CVR Agreement.  The Company shall take prompt steps to have a successor appointed in the manner provided in this CVR Agreement.

     

    (b)         If

          the Trustee fails to comply with Section 4.8(a), the Trustee shall, within ten (10) days of the expiration of such ninety (90) day period, transmit a notice of such failure to the
          Holders in the manner and to the extent provided in the Trust Indenture Act and this CVR Agreement.

     

    (c)          If

          the Trustee fails to comply with Section 4.8(a) after written request therefore by the Company or any Holder, then any Holder of any Security who has been a bona fide Holder for at
          least six (6) months may on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the removal of such Trustee and the appointment of a successor Trustee.

     

    Section 4.9          Corporate Trustee Required; Eligibility.  There shall at all times be a Trustee hereunder which satisfies the applicable requirements of Sections 310(a)(1) and (5) of the Trust Indenture Act and
      which, along with its Affiliates, has a combined capital and surplus of at least one hundred fifty million dollars ($150,000,000).  If the Trustee publishes reports of condition at least annually, pursuant to Law or to the requirements of a
      supervising or examining authority, then for the purposes of this Section 4.9, the combined capital and surplus of the Trustee shall be deemed to be its combined capital and surplus as set
      forth in its most recent report of condition so published.  If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section 4.9, it shall resign
      immediately in the manner and with the effect hereinafter specified in this Article 4.

     

    Section 4.10      
        Resignation and Removal; Appointment of Successor.

     

    (a)          No resignation or removal of the Trustee and no appointment of a successor Trustee pursuant to this Article 4 shall become effective until the acceptance of appointment by the
          successor Trustee under Section 4.11.

     

    
      24

      
        

    

    (b)         The

          Trustee, or any trustee or trustees hereafter appointed, may resign at any time by giving written notice thereof to the Company.  If an instrument of acceptance by a successor Trustee shall not have been delivered to the Trustee within thirty
          (30) days after the giving of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor Trustee.

     

    (c)          The Trustee may be removed at any time by an act of the Majority Holders, delivered to the Trustee and to the Company.

     

    (d)          If at any time:

     

    (i)          the Trustee shall fail to comply with Section 4.8 after written request therefor by the Company or by any Holder who has been a bona fide Holder of a Security for at least six
          (6) months, or

     

    (ii)         the Trustee shall cease to be eligible under Section 4.9 and shall fail to resign after written request therefor by the Company or by any such Holder, or

     

    (iii)        the Trustee shall become incapable of acting or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its
          property or affairs for the purpose of rehabilitation, conservation or liquidation,

     

    then, in any case, (A) the Company, by a Board Resolution or an action of the chief executive officer of the Company, may remove the Trustee, or (B) the Holder of any
      Security who has been a bona fide Holder of a Security for at least six (6) months may, on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a
      successor Trustee.

     

    (e)         If

          the Trustee shall resign, be removed or become incapable of acting, or if a vacancy shall occur in the office of Trustee for any cause, the Company, by a Board Resolution or an action of the chief executive officer of the Company, shall promptly
          appoint a successor Trustee.  If, within one year after any resignation, removal or incapacity, or the occurrence of such vacancy, a successor Trustee shall be appointed by act of the Majority Holders delivered to the Company and the retiring
          Trustee, then the successor Trustee so appointed shall, forthwith upon its acceptance of such appointment in accordance with Section 4.11, become the successor Trustee and supersede the
          successor Trustee appointed by the Company.  If no successor Trustee shall have been so appointed by the Company or the Majority Holders and accepted appointment within sixty (60) days after the retiring Trustee tenders its resignation or is
          removed, the retiring Trustee may, or, the Holder of any Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the
          appointment of a successor Trustee.

     

    (f)          The Company shall give notice of each resignation and each removal of the Trustee and each appointment of a successor Trustee by mailing written notice of such event by first-class mail, postage prepaid, to the Holders of Securities as
          their names and addresses appear in the Security Register.  Each notice shall include the name of the successor Trustee and the address of its Corporate Trust Office.  If the Company fails to send such notice within ten (10) days after acceptance
          of appointment by a successor Trustee, it shall not be a default hereunder but the successor Trustee shall cause the notice to be mailed at the expense of the Company.

     

    
      25

      
        

    

    Section 4.11       
      Acceptance of Appointment of Successor.

     

    (a)         Every

          successor Trustee appointed hereunder shall execute, acknowledge and deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become
          effective and such successor Trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee; but, upon request of the Company or the successor Trustee, such
          retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor Trustee all the rights, powers and trusts of the retiring Trustee, and shall duly assign, transfer and deliver to such successor
          Trustee all property and money held by such retiring Trustee hereunder.  Upon request of any such successor Trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor
          Trustee all such rights, powers and trusts.

     

    (b)         No

          successor Trustee shall accept its appointment unless at the time of such acceptance such successor Trustee shall be qualified and eligible under this Article 4.

     

    Section 4.12       
      Merger, Conversion, Consolidation or Succession to Business.  Any Person into which the Trustee may be merged or converted or with which it may be consolidated, or any Person resulting from
      any merger, conversion or consolidation to which the Trustee shall be a party, or any Person succeeding to all or substantially all of the corporate trust business of the Trustee, by sale or otherwise shall be the successor of the Trustee hereunder,
      provided such Person shall be otherwise qualified and eligible under this Article 4, without the execution or filing of any paper or any further act on the part of any of the Parties
      hereto.  In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion, sale or consolidation to such authenticating Trustee may adopt such authentication and deliver the
      Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities; provided that the right to adopt the certificate of authentication of
      any predecessor Trustee shall apply only to its successor or successors by merger, conversion or consolidation.

     

    Section 4.13       
      Preferential Collection of Claims Against Company.  If and when the Trustee shall be or shall become a creditor, directly or indirectly, secured or unsecured, of the Company (or any other
      obligor upon the Securities), excluding any creditor relationship set forth in Section 311(b) of the Trust Indenture Act, if applicable, the Trustee shall be subject to the applicable provisions of the Trust Indenture Act regarding the collection of
      claims against the Company (or any such other obligor).

     

    
      26

      
        

    

    ARTICLE 5

      HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY

     

    Section 5.1        
      Company to Furnish Trustee Names and Addresses of Holders.  The Company will furnish or cause to be furnished to the Trustee (a) promptly after the issuance of the Securities, and
      semi-annually thereafter, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a recent date, and (b) at such times as the Trustee may request in writing, within thirty (30) days after receipt by
      the Company of any such request, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a date not more than fifteen (15) days prior to the time such list is furnished; provided, however, that if and so long as the Trustee shall be the Security Registrar, no such list need be furnished.

     

    Section 5.2          Preservation of Information; Communications to Holders.

     

    (a)        The

          Trustee shall preserve, in as current a form as is reasonably practicable, the names and addresses of the Holders contained in the most recent list furnished to the Trustee as provided in Section
              5.1 and the names and addresses of Holders received by the Trustee in its capacity as Security Registrar.  The Trustee may destroy any list furnished to it as
            provided in Section 5.1 upon receipt of a new list so furnished.

     

    (b)         The

        rights of the Holders to communicate with other Holders with respect to their rights under this CVR Agreement and the corresponding rights and privileges of the Trustee shall be as provided by Section 312(b)(2) of the Trust Indenture Act, if
        applicable.

     

    (c)         Every

          Holder of Securities, by receiving and holding the same, agrees with the Company and the Trustee that neither the Company nor the Trustee shall be deemed to be in violation of Law or held accountable by reason of the disclosure of any such
          information as to the names and addresses of the Holders made in accordance with Section 5.2(b) regardless of the source from which such information was derived, and that the Trustee
          shall not be held accountable by reason of providing any information pursuant to a request made under Section 5.2(b).

     

    Section 5.3     
           Reports by Trustee.

     

    (a)         Within

          sixty (60) days after December 31 of each year commencing with the December 31 following the date of this CVR Agreement, the Trustee shall transmit to all Holders such reports concerning the Trustee and its actions under this CVR Agreement as may
          be required pursuant to Section 313 of the Trust Indenture Act to the extent and in the manner provided pursuant thereto.  The Trustee shall also comply with Section 313(b)(2) of the Trust Indenture Act, if applicable.  The Trustee shall also
          transmit by mail all reports as required by Section 313(c) of the Trust Indenture Act, if applicable.

     

    (b)         A
          copy of each such report shall, at the time of such transmission to the Holders, be filed by the Trustee with each stock exchange, if any, upon which the Securities are listed, with the Commission and also with the Company.  The Company will
          promptly notify the Trustee when the Securities are listed on any stock exchange.

     

    
      27

      
        

    

    Section 5.4           Reports by Company.

     

    (a)         The

          Company shall file with the Trustee, within fifteen (15) days after the Company files or furnishes the same with the Commission, copies of an annual report filed on Form 10-K or a quarterly reports filed on Form 10-Q
          and of the information, documents and other reports (or copies of such portions of any of the foregoing as the Commission may from time to time by rules and regulations prescribe) which the Company is required to file with the Commission pursuant
          to Section 13 or Section 15(d) of the Exchange Act (such annual and quarterly reports and required information, documents and other reports, together the “Exchange Act Documents”).

     

    (b)        Delivery

          of the reports, information and documents described in Section 5.4(a) shall not constitute constructive notice of any information contained therein or determinable there from, including
          the Company’s compliance with any of its covenants or other obligations hereunder as to which the Trustee is entitled to rely exclusively on Officer’s Certificates.

     

    ARTICLE 6

      AMENDMENTS

     

    Section 6.1          Amendments Without Consent of Holders.  Without the consent of any Holders, the Company and the Trustee, at any time and from time to time, may enter into one or more amendments hereto or to the
      Securities, for any of the following purposes:

     

    (a)          to convey, transfer, assign, mortgage or pledge to the Trustee as security for the Securities any property or assets;

     

    (b)          to evidence the succession of another Person to the Company, and the assumption by any such successor of the covenants of the Company herein and in the Securities;

     

    (c)        to

          add to the covenants of the Company such further covenants, restrictions, conditions or provisions as the Company and the Trustee shall consider to be for the protection of the Holders of Securities, and to make the occurrence, or the occurrence
          and continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default permitting the enforcement of all or any of the several remedies provided in this CVR Agreement as herein set forth; provided, that in respect of any such additional covenant, restriction, condition or provision, such amendment may provide for a particular period of grace after default (which period may be
          shorter or longer than that allowed in the case of other defaults) or may provide for an immediate enforcement upon such an Event of Default or may limit the remedies available to the Trustee upon such an Event of Default or may limit the right
          of the Majority Holders to waive such an Event of Default;

     

    (d)         to

          cure any ambiguity, or to correct or supplement any provision herein or in the Securities which may be defective or inconsistent with any other provision herein; provided, that such provisions shall not materially reduce the benefits of this CVR
          Agreement or the Securities to the Holders;

     

    
      28

      
        

    

    (e)          to make any other provisions with respect to matters or questions arising under this CVR Agreement; provided, that such provisions shall not adversely affect the interests of
          the Holders;

     

    (f)           to make any amendments or changes necessary to comply or maintain compliance with the Trust Indenture Act, if applicable; or

     

    (g)          make any other change that does not adversely affect the interests of the Holders.

     

    Promptly following any amendment of this CVR Agreement or the Securities in accordance with this Section 6.1,
      the Trustee shall notify the Holders of the Securities of such amendment; provided that any failure so to notify the Holders shall not affect the validity of such amendment.

     

    Section 6.2       
        Amendments with Consent of Holders.  With the consent of the Majority Holders, by Act of said Holders delivered to the Company and the Trustee, the Company (when authorized by a Board
      Resolution or the chief executive officer of the Company) and the Trustee may enter into one or more amendments hereto or to the Securities for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of
      this CVR Agreement or to the Securities or of modifying in any manner the rights of the Holders under this CVR Agreement or to the Securities; provided, however, that no such amendment shall, without the consent of the Holder of each Outstanding Security affected thereby:

     

    (a)         modify

          in a manner adverse to the Holders (i) any provision contained herein with respect to the termination of this CVR Agreement or the Securities, (ii) the time for payment and amount of the Milestone Payment, or otherwise extend the time for payment
          of the Securities or reduce the amounts payable in respect of the Securities or modify any other payment term or payment date;

     

    (b)          reduce the number of CVRs, the consent of whose Holders is required for any such amendment; or

     

    (c)         modify

          any of the provisions of this Section 6.2, except to increase the percentage of Holders from whom consent or approval is required or to provide that certain other provisions of this CVR
          Agreement cannot be modified or waived without the consent of the Holder of each Security affected thereby.

     

    It shall not be necessary for any Act of Holders under this Section 6.2 to approve the
      particular form of any proposed amendment, but it shall be sufficient if such Act shall approve the substance thereof.

     

    Section 6.3          Execution of Amendments.  In executing any amendment permitted by this Article 6, the Trustee shall be entitled to receive, and
      (subject to Section 4.1) shall be fully protected in relying upon, an Opinion of Counsel stating that the execution of such amendment is authorized or permitted by this CVR Agreement.  The
      Trustee shall execute any amendment authorized pursuant to this Article 6 if the amendment does not adversely affect the Trustee’s own rights, duties or immunities under this CVR Agreement
      or otherwise.  Otherwise, the Trustee may, but need not, execute such amendment.

     

    
      29

      
        

    

    Section 6.4          Effect of Amendments; Notice to Holders.

     

    (a)         Upon

          the execution of any amendment under this Article, this CVR Agreement and the Securities shall be modified in accordance therewith, and such amendment shall form a part of this CVR Agreement and the Securities for all purposes; and every Holder
          of Securities theretofore or thereafter authenticated, as applicable, and delivered hereunder shall be bound thereby.

     

    (b)        Promptly

          after the execution by the Company and the Trustee of any amendment pursuant to the provisions of this Article 6, the Company shall mail a notice thereof by first class mail to the
          Holders of Securities at their addresses as they shall appear on the Security Register, setting forth in general terms the substance of such amendment.  Any failure of the Company to mail such notice, or any defect therein, shall not, however, in
          any way impair or affect the validity of any such amendment.

     

    Section 6.5      
          Conformity with Trust Indenture Act.  Every amendment executed pursuant to this Article 6 shall conform to the applicable
      requirements of the Trust Indenture Act, if any.

     

    Section 6.6        
      Reference in Securities to Amendments.  If an amendment changes the terms of a Security, the Trustee may require the Holder of the Security to deliver it to the Trustee.  Global Securities
      authenticated and delivered after the execution of any amendment pursuant to this Article 6 may, and shall if required by the Trustee, bear a notation in form approved by the Trustee as to
      any matter provided for in such amendment.  If the Company shall so determine, new Securities so modified as to conform, in the opinion of the Trustee, on the on hand, and the Board of Directors or the chief executive officer of the Company, on the
      other hand, to any such amendment may be prepared and executed by the Company, as applicable, and authenticated, as applicable, and delivered by the Trustee in exchange for Outstanding
      Securities.  Failure to make the appropriate notation or to issue a new Security shall not affect the validity of such amendment.

     

    ARTICLE 7

      COVENANTS

     

    Section 7.1          Payment of Amounts, if any, to Holders. 
      The Company will duly and punctually pay the amounts due, if any, on the Securities in accordance with the terms of this CVR Agreement.  Such amounts shall be considered paid on the Milestone Payment Date if on or prior to such date the Company
      makes, or causes to be made, the payment required pursuant to Section 3.1(c) of this CVR Agreement.  Notwithstanding any other provision of this CVR Agreement, the Company or any of its
      Affiliates, the Trustee or the Paying Agent, shall be entitled to deduct and withhold, or cause to be deducted and withheld, from any amounts payable or otherwise deliverable pursuant
        to this CVR Agreement to any Person, such amounts as are required to be deducted and withheld therefrom under the Code, or any provision of state, local or foreign Tax Law. To the extent that amounts are so deducted and withheld by the Company or any of its Affiliates, the Trustee or the Paying Agent, such withheld amounts shall be (a) paid over to the applicable Governmental
        Entity in accordance with applicable Law and (b) treated for all purposes of this CVR Agreement as having been paid to the Person in respect of which such deduction and withholding was made by the Company or any of its Affiliates, the Trustee or
        the Paying Agent, as the case may be.  The consent of Holder shall not be required for any such withholding.

     

    
      30

      
        

    

    Section 7.2          

      Maintenance of Office or Agency.

     

    (a)         As

          long as any of the Securities remain Outstanding, the Company will maintain an office or agency (i) where Securities may be presented or surrendered for payment, (ii) where Securities may be surrendered for registration of transfer or exchange
          and (iii) where notices and demands to or upon the Company in respect of the Securities and this CVR Agreement may be served.  The office or agency of the Trustee at 1110 Centre Pointe Curve, Suite 101 Mendota Heights, Minnesota 55120-4101 shall
          be such office or agency of the Company, unless the Company shall designate and maintain some other office or agency for one or more of such purposes.  The Company or any of its Subsidiaries may act as Paying Agent, registrar or transfer agent;
          provided that such Person shall take appropriate actions to avoid the commingling of funds.  The Company will give prompt written notice to the Trustee of any change in the location of any such office or agency.  If at any time the Company shall
          fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all
          such presentations, surrenders, notices and demands.

     

    (b)        The

          Company may from time to time designate one or more other offices or agencies where the Securities may be presented or surrendered for any or all such purposes, and may from time to time rescind such designation; provided, however, that no such
          designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency for such purposes.  The Company will give prompt written notice to the Trustee of any such designation or rescission and any
          change in the location of any such office or agency.

     

    Section 7.3        
        Money for Security Payments to Be Held in Trust.

     

    (a)          If the Company or any of its Subsidiaries shall at any time act as the Paying Agent, it will, on or before the Milestone Payment Date segregate and hold in trust for the benefit of the Holders all sums held by such Paying Agent for
          payment on the Securities until such sums shall be paid to the Holders as herein provided, and will promptly notify the Trustee of such action or any failure to so act.

     

    (b)         Whenever

          the Company shall have one or more Paying Agents for the Securities, it will, on or before the Milestone Payment Date deposit with a Paying Agent a sum in same day funds sufficient to pay the amount, if any, so becoming due; such sum to be held
          in trust for the benefit of the Persons entitled to such amount, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee of such action or any failure so to act.

     

    (c)         The

          Company will cause each Paying Agent other than the Trustee to execute and deliver to the Trustee an instrument in which such Paying Agent shall agree with the Trustee, subject to the provisions of this Section 7.3, that such Paying Agent will (i) hold all sums held by it for the payment of any amount payable on Securities in trust for the benefit of the Persons entitled thereto until such sums shall be paid to such
          Persons or otherwise disposed of as herein provided and will notify the Trustee of the sums so held, and (ii) give the Trustee notice of any failure by the Company (or by any other obligor on the Securities) to make any payment on the Securities
          when the same shall be due and payable.

     

    
      31

      
        

    

    (d)         Any

          money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment on any Security and remaining unclaimed for one year after the Milestone Payment Date shall be paid to the Company on Company Request, or
          (if then held by the Company) shall be discharged from such trust; and the Holder of such Security shall thereafter, as an unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying
          Agent with respect to such trust money shall thereupon cease.

     

    Section 7.4          Certain Purchases and Sales.  Nothing contained herein shall prohibit the Company or any of its Subsidiaries or Affiliates from acquiring in open market transactions, private transactions or
      otherwise, any Securities.

     

    Section 7.5          Books and Records.  During the term of this CVR Agreement and for a period of three (3) years after the Termination Date, the Company shall use commercially reasonable efforts to keep, and shall
      cause its Subsidiaries to use commercially reasonable efforts to keep, true, complete and accurate records in reasonably sufficient detail to enable the Holders to determine if the Company has complied with its obligations under this CVR Agreement.

     

    Section 7.6          Listing of CVRs.  The Company hereby covenants and agrees to use reasonable best efforts to cause the Securities to be approved for listing (subject to notice of issuance) for trading on the New
      York Stock Exchange or other national securities exchange and will use its reasonable best efforts to maintain such listing for so long as any CVRs remain Outstanding.

     

    Section 7.7          Product Transfer.  If the Company or its Affiliates, directly or indirectly, by a sale or swap of assets, merger,
      reorganization, joint venture, lease, license or any other transaction or arrangement, sells, transfers, conveys or otherwise disposes of its respective rights in and to any Product to a third party (other than the Company or any of its
      Subsidiaries), then the applicable Milestone for such Product (e.g., if the Product is BB2121, then the BB2121 Milestone) shall be deemed to have been satisfied for all purposes under this CVR Agreement as of the earlier of the entry into a
      definitive agreement with respect to, and the consummation of, the transaction or arrangement involving such sale, transfer, conveyance or other disposition; provided, that if such sale,
      transfer, conveyance or other disposition is permitted by Section 9.1, then Section 9.1 shall govern.  For the purposes of
      clarification, and subject to Section 7.8, the Company may use contract research organizations, contract manufacturing organizations, contract sales organizations, subcontractors and
      distributors in the ordinary course of business to perform research, development, manufacturing and commercialization activities (including granting an appropriate sublicense to the extent necessary), without triggering the applicable Milestone.

     

    Section 7.8          Diligent Efforts.  The Company shall use Diligent Efforts to achieve the Milestone.

     

    
      32

      
        

    

    Section 7.9         Confidentiality.  The Trustee and the Holders hereby agree that any confidential or non-public information they receive from or on behalf of the Company or any Affiliate of the Company, which receipt arises out of the
      transactions contemplated by this CVR Agreement (the “Confidential Information”), shall: (a) not be used for any purpose other than for purposes permitted under this CVR Agreement; (b) not
      be used directly or indirectly in any way that is for competitive purposes; and (c) not be disclosed by, and be kept confidential by, such Trustee and the Holders and its directors, officers, members, managers, employees, affiliates and agents
      (collectively, “Representatives”); provided, however, that any such
      Confidential Information may be disclosed only to their Representatives who (i) need to know such Confidential Information and (ii) are bound in writing to a non-disclosure agreement no less restrictive than this Section 7.9.  It is understood that such Representatives shall be informed by the Trustee or the applicable Holder of the confidential nature of such Confidential Information, and that the Trustee or such Holder, as
      applicable, shall be responsible for any disclosure or use made by its Representatives in breach of obligations under this CVR Agreement to the same extent as if such disclosure or use had been made directly by the Trustee or such Holder, as
      applicable.  Each of the Trustee and the Holders will as soon as practicable notify the Company of any breach of this CVR Agreement of which they become aware, and will use commercially reasonable efforts to assist and cooperate with the Company in
      minimizing the consequences of such breach.  “Confidential Information” shall not include any information that is (A) publicly available other than because of or related to any disclosure by the Trustee or the Holders or any of
      their respective Representatives or (B) is lawfully disclosed to the Trustee or Holders by sources (other than the Company or its Affiliates) rightfully in possession of the Confidential Information on a non-confidential basis.  If the Trustee,
      Holders or their respective Representatives are legally required or requested to disclose any Confidential Information, they will in advance of such disclosure, unless otherwise prohibited by Law, promptly notify the Company in writing of such
      request or requirement so that the Company may seek to avoid or minimize the required disclosure and/or obtain an appropriate protective order or other appropriate relief to ensure that any Confidential Information so disclosed is maintained in
      confidence to the maximum extent possible by the person receiving the disclosure, or, in the Company’s discretion, to waive compliance with the provisions of this CVR Agreement.  In
        any such case, the Trustee and the Holders agree to cooperate and use reasonable efforts to avoid or minimize the required disclosure and/or obtain such protective order or other relief.  If, in the absence of a protective order or the receipt of a
        waiver hereunder, the Trustee, Holders or their respective Representatives are legally obligated to disclose any Confidential Information, they will disclose only so much thereof to the party compelling disclosure as they believe in good faith, on
        the basis of advice of counsel, is required by Law. The Trustee and Holders shall, unless otherwise prohibited by Law, give the Company prior written notice of the specific Confidential Information that they believe they are required to disclose
        under such circumstances.  All Confidential Information disclosed by or on behalf of the Company or any of its Affiliates shall be, and shall remain, the property of the Company or such Affiliate.

     

    Section 7.10       
      Non-Use of Name.  Neither the Trustee nor the Holders shall use the name, trademark, trade name, or logo of the Company, its Affiliates or their respective employees, agents or
      representatives in any publicity or news release relating to this CVR Agreement or its subject matter, without the prior express written permission of the Company.

     

    
      33

      
        

    

    Section 7.11         Notice of Default.  The Company shall file with the Trustee written notice of the occurrence of any Event of Default or other default under this CVR Agreement within five (5) Business Days of its becoming aware of
      such Event of Default or other default.

     

    ARTICLE 8

      REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT

     

    Section 8.1          Event of Default Defined; Waiver of Default.  “Event of Default”
      with respect to the Securities, means each one of the following events which shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of Law or
      pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body):

     

    (a)          default in the payment by the Company pursuant to the terms of this CVR Agreement of all or any part of the Milestone Payment after a period of ten (10) Business Days after the Milestone Payment shall become due and payable on the
          Milestone Payment Date; or

     

    (b)         material

          default in the performance, or breach in any material respect, of any covenant or warranty of the Company in respect of the Securities (other than a covenant or warranty in respect of the Securities, a default in whose performance or whose breach
          is elsewhere in this Section 8.1 specifically dealt with), and continuance of such default or breach for a period of ninety (90) days after there has been given, by registered or
          certified mail, to the Company by the Trustee or to the Company and the Trustee by the Majority Holders, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or

     

    (c)         a
          court having jurisdiction in the premises shall enter a decree or order for relief in respect of the Company in an involuntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or appointing a
          receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of the Company or for any substantial part of its property or ordering the winding up or liquidation of its affairs, and such decree or order shall remain
          unstayed and in effect for a period of ninety (90) consecutive days; or

     

    (d)         the

          Company shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or consent to the entry of an order for relief in an involuntary case under any such Law, or consent to the
          appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of the Company or for any substantial part of its property, or make any general assignment for the benefit of
          creditors.

     

    If an Event of Default described above occurs and is continuing, then, and in each and every such case, either the Trustee by notice in writing to the
      Company or the Trustee upon the written request of the Majority Holders by notice in writing to the Company (and to the Trustee if given by the Majority Holders), shall bring suit to protect the rights of the Holders, including to obtain payment for
      any amounts then due and payable, which amounts shall bear interest at the Default Interest Rate from the date such amounts were due and payable hereunder until payment is made to the Trustee.

     

    
      34

      
        

    

    The foregoing provisions of this Section 8.1, however, are subject to the condition that
      if, at any time after the Trustee shall have begun such suit, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a
      sum sufficient to pay all amounts which shall have become due (with interest upon such overdue amount at the Default Interest Rate to the date of such payment or deposit) and such amount as shall be sufficient to cover reasonable compensation to the
      Trustee, its agents, attorneys and counsel, and all other expenses and liabilities incurred and all advances made, by the Trustee, and if any and all Events of Default under this CVR Agreement shall have been cured, waived or otherwise remedied as
      provided herein, then and in every such case the Majority Holders, by written notice to the Company and to the Trustee, may waive all defaults with respect to the Securities, but no such waiver or rescission and annulment shall extend to or shall
      affect any subsequent default or shall impair any right consequent thereof.

     

    Section 8.2        
      Collection by the Trustee; the Trustee May Prove Payment Obligations.  The Company covenants that in case default shall be made in the payment of all or any part of the Securities when the
      same shall have become due and payable, whether at the Milestone Payment Date or otherwise, then upon demand of the Trustee, the Company will pay to the Trustee for the benefit of the Holders of the Securities the whole amount that then shall have
      become due and payable on all Securities (with interest from the date due and payable to the date of such payment upon the overdue amount at the Default Interest Rate); and in addition thereto, such further amount as shall be sufficient to cover the
      costs and expenses of collection, including reasonable compensation to the Trustee and each predecessor Trustee, their respective agents, attorneys and counsel, and any expenses and liabilities incurred, and all advances made, by the Trustee and each
      predecessor Trustee, except as a result of its negligence, bad faith or willful misconduct.

     

    In case the Company shall fail forthwith to pay such amounts upon such demand, the Trustee, in its own name and as trustee of an express trust, shall
      be entitled and empowered to institute any action or proceedings at Law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceedings to judgment or final decree, and may enforce any such judgment or
      final decree against the Company or other obligor upon such Securities and collect in the manner provided by Law out of the property of the Company or other obligor upon such Securities, wherever situated, the moneys adjudged or decreed to be
      payable.

     

    In any judicial proceedings relative to the Company or other obligor upon the Securities, irrespective of whether any amount is then due and payable
      with respect to the Securities, the Trustee is authorized:

     

    (a)         to

          file and prove a claim or claims for the whole amount owing and unpaid in respect of the Securities, and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for
          reasonable compensation to the Trustee and each predecessor Trustee, and their respective agents, attorneys and counsel, and for reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor
          Trustee, except as a result of negligence, bad faith or willful misconduct) and of the Holders allowed in any judicial proceedings relative to the Company or other obligor upon the Securities, or to their respective property;

     

    
      35

      
        

    

    (b)         unless

          prohibited by and only to the extent required by applicable Law, to vote on behalf of the Holders in any election of a trustee or a standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings or
          person performing similar functions in comparable proceedings; and

     

    (c)          to collect and receive any moneys or other property payable or deliverable on any such claims, and to distribute all amounts received with respect to the claims of the Holders and of the Trustee on their behalf; and any trustee,
          receiver, or liquidator, custodian or other similar official is hereby authorized by each of the Holders to make payments to the Trustee, and, in the event that the Trustee shall consent to the making of payments directly to the Holders, to pay
          to the Trustee such amounts as shall be sufficient to cover reasonable compensation to the Trustee, each predecessor Trustee and their respective agents, attorneys and counsel, and all other expenses and liabilities incurred, and all advances
          made, by the Trustee and each predecessor Trustee, except as a result of its negligence, bad faith or willful misconduct, and all other amounts due to the Trustee or any predecessor Trustee pursuant to Section 4.7.  To the extent that such
          payment of reasonable compensation, expenses, disbursements, advances and other amounts out of the estate in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and
          all distributions, dividends, moneys, securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or arrangement or otherwise.

     

    Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or vote for or accept or adopt on behalf of any Holder
      any plan of reorganization, arrangement, adjustment or composition affecting the Securities, or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding except, as aforesaid,
      to vote for the election of a trustee in bankruptcy or similar person.

     

    All rights of action and of asserting claims under this CVR Agreement, or under any of the Securities, may be enforced by the Trustee without the
      possession of any of the Securities or the production thereof and any trial or other proceedings instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment, subject to the payment of the
      expenses, disbursements and compensation of the Trustee, each predecessor Trustee and their respective agents and attorneys, shall be for the ratable benefit of the Holders.

     

    In any proceedings brought by the Trustee (and also any proceedings involving the interpretation of any provision of this CVR Agreement to which the
      Trustee shall be a party) the Trustee shall be held to represent all the Holders, and it shall not be necessary to make any Holders of such Securities parties to any such proceedings.

     

    Section 8.3        
      Application of Proceeds.  Any monies collected by the Trustee pursuant to this Article 8 in respect of any Securities shall be
      applied in the following order at the date or dates fixed by the Trustee upon presentation of the several Securities in respect of which monies have been collected and stamping (or otherwise noting) thereon the payment in exchange for the presented
      Securities if only partially paid or upon surrender thereof if fully paid:

     

    
      36

      
        

    

    FIRST: To the payment of costs and expenses in respect of which monies have been collected, including reasonable compensation to the Trustee and each
      predecessor Trustee and their respective agents and attorneys and of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence, bad faith or willful misconduct, and
      all other amounts due to the Trustee or any predecessor Trustee pursuant to Section 4.7;

     

    SECOND: To the payment of the whole amount then owing and unpaid upon all the Securities, with interest at the Default Interest Rate on all such
      amounts, and in case such monies shall be insufficient to pay in full the whole amount so due and unpaid upon the Securities, then to the payment of such amounts without preference or priority of any security over any other Security, ratably to the
      aggregate of such amounts due and payable; and

     

    THIRD: To the payment of the remainder, if any, to the Company or any other person lawfully entitled thereto.

     

    Section 8.4       
        Suits for Enforcement.  In case an Event of Default has occurred, has not been waived and is continuing, the Trustee may in its discretion proceed to protect and enforce its rights and
      the rights of the Holders under this CVR Agreement by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either at Law or in equity or in bankruptcy or otherwise, whether for the
      specific enforcement of any covenant or agreement contained in this CVR Agreement or in aid of the exercise of any power granted in this CVR Agreement or to enforce any other legal
        or equitable right vested in the Trustee by this CVR Agreement or by Law.

     

    Section 8.5       
        Restoration of Rights on Abandonment of Proceedings.  In case the Trustee or any Holder shall have proceeded to enforce any right under this CVR Agreement and such proceedings shall,
      subject to any determination in such proceeding, have been discontinued or abandoned for any reason, or shall have been determined adversely to the Trustee or to such Holder, then and in every such case the Company and the Trustee and the Holders
      shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company, the Trustee and the Holders shall continue as though no such proceedings had been taken.

     

    Section 8.6        
        Limitations on Suits by Holders.  Subject to the rights of the Holders under Section 8.7, no Holder of any Security shall have
      any right by virtue or by availing of any provision of this CVR Agreement to institute any action or proceeding at Law or in equity or in bankruptcy or otherwise upon or under or with respect to this CVR Agreement, or for the appointment of a
      trustee, receiver, liquidator, custodian or other similar official or for any other remedy hereunder, unless such Holder previously shall have given to the Trustee written notice of default and of the continuance thereof, as hereinbefore provided,
      and unless the Majority Holders shall also have made written request upon the Trustee to institute such action or proceedings in its own name as trustee hereunder and shall have offered to the Trustee such reasonable indemnity as it may require
      against the costs, expenses and liabilities to be incurred therein or thereby and the Trustee for fifteen (15) days after its receipt of such notice, request and offer of indemnity shall have failed to institute any such action or proceeding and no
      direction inconsistent with such written request shall have been given to the Trustee pursuant to Section 8.9; it being understood and intended that no one or more of such Holders may
      obtain or seek to obtain priority or preference over any other of such Holders or to enforce any right under this CVR Agreement, except for the equal and ratable benefit of all such Holders.  For the protection and enforcement of the provisions of
      this Section 8.6, each and every Holder and the Trustee shall be entitled to such relief as can be given either at Law or in equity.

     

    
      37

      
        

    

    Section 8.7        
      Unconditional Right of Holders to Institute Certain Suits.  Notwithstanding any other provision in this CVR Agreement and any provision of any Security, the right of any Holder of any
      Security to receive payment of the amounts payable in respect of such Security on or after the respective due dates expressed in such Security, or to institute suit for the enforcement of any such payment on or after such respective dates, shall not
      be impaired or affected without the consent of such Holder.

     

    Section 8.8       
         Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default.

     

    (a)          Except as provided in Section 8.6, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or
          remedy, and every right and remedy shall, to the extent permitted by Law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at Law or in equity or otherwise.  The assertion or employment of
          any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy.

     

    (b)         No

          delay or omission of the Trustee or of any Holder to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall impair any such
            right or power or shall be construed to be a waiver of any such Event of Default or an acquiescence therein; and, subject to Section 8.6, every power and remedy given by this CVR Agreement or by Law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the
            Trustee or by the Holders.

     

    Section 8.9          Control by Holders.

     

    (a)         The

          Majority Holders shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any power conferred on the Trustee with respect to the Securities by this CVR
          Agreement; provided that such direction shall not be otherwise than in accordance with Law and the provisions of this CVR Agreement; and provided further that (subject to the provisions of Section 4.1) the Trustee shall have the right to decline to follow any such direction
          if the Trustee, being advised by counsel, shall determine that the action or proceeding so directed may not lawfully be taken or if the Trustee in good faith by its board of directors, the executive committee, or a committee of directors or
          Responsible Officers of the Trustee shall determine that the action or proceedings so directed would involve the Trustee in personal liability or if the Trustee in good faith shall so determine that the actions or forbearances specified in or
          pursuant to such direction would be unduly prejudicial to the interests of Holders of the Securities not joining in the giving of said direction.

     

    
      38

      
        

    

    (b)         Nothing

          in this CVR Agreement shall impair the right of the Trustee in its discretion to take any action deemed proper by the Trustee and which is not inconsistent with such direction or directions by Holders.

     

    Section 8.10       
      Waiver of Past Defaults.

     

    (a)         In

          the case of a default or an Event of Default specified in clause (b), (c) or (d) of Section 8.1, the Majority Holders may waive any such default or Event of Default, and its
          consequences except a default in respect of a covenant or provisions hereof which cannot be modified or amended without the consent of the Holder of each Security affected.  In the case of any such waiver, the Company, the Trustee and the Holders
          of the Securities shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.

     

    (b)        Upon

          any such waiver, such default shall cease to exist and be deemed to have been cured and not to have occurred, and any Event of Default arising therefrom shall be deemed to have been cured, and not to have occurred for every purpose of this CVR
          Agreement; but no such waiver shall extend to any subsequent or other default or Event of Default or impair any right consequent thereon.

     

    Section 8.11       
      The Trustee to Give Notice of Default, But May Withhold in Certain Circumstances.  The Trustee shall transmit to the Holders, as the names and addresses of such Holders appear on the
      Security Register (as provided under Section 313(c) of the Trust Indenture Act, if applicable), notice by mail of all defaults which have occurred and are known to the Trustee, such notice to be transmitted within ninety (90) days after the
      occurrence thereof, unless such defaults shall have been cured before the giving of such notice (the term “default” for the purposes of this Section being
        hereby defined to mean any event or condition which is, or with notice or lapse of time or both would become, an Event of Default); provided that, except in the case of default in the payment of the amounts payable in respect of any of the
        Securities, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee, or a trust committee of directors or trustees and/or Responsible Officers of the Trustee in good faith
        determines that the withholding of such notice is in the interests of the Holders.

     

    Section 8.12       
      Right of Court to Require Filing of Undertaking to Pay Costs.  All Parties to this CVR Agreement agree, and each Holder of any Security by his acceptance thereof shall be deemed to have
      agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this CVR Agreement or in any suit against the Trustee for any action taken, suffered or omitted by it as the Trustee, the filing by any
      party litigant in such suit of an undertaking to pay the reasonable out-of-pocket costs of such suit, and that such court may in its discretion assess reasonable out-of-pocket costs, including reasonable out-of-pocket attorneys’ fees, against any
      party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section 8.12 shall not apply to
      any suit instituted by the Trustee, to any suit instituted by any Holder or group of Holders holding in the aggregate more than ten percent (10%) of the Securities Outstanding or to any suit
      instituted by any Holder for the enforcement of the payment of any Security on or after the due date expressed in such Security.

     

    
      39

      
        

    

    ARTICLE 9

      CONSOLIDATION, MERGER, SALE OR CONVEYANCE

     

    Section 9.1         Company May Consolidate, etc., on Certain Terms.  The Company covenants that it will not merge or consolidate
      with or into any other Person or sell or convey all or substantially all of its assets to any Person, unless (a) either (i) the Company shall be the continuing Person or (ii) the successor Person, or the Person that acquires by sale or conveyance
      substantially all the assets of the Company shall be a Person organized under the Laws of the United States of America or any State thereof, any member of the European Union or the United Kingdom and shall expressly assume, by an assignment and
      assumption agreement, executed and delivered to the Trustee, in substantially the form attached hereto as Annex B, the due and punctual payment of the Milestone Payment and the due and
      punctual performance and observance of all covenants and conditions of this CVR Agreement to be performed or observed by the Company, and (b) immediately after such merger or consolidation, or such sale or conveyance, no default or Event of Default
      shall have occurred and be continuing.

     

    Section 9.2        
        Successor Person Substituted.

     

    (a)          In case of an assumption pursuant to Section 9.1(a)(ii), such assuming Person shall succeed to and be substituted for the Company with the same effect as if it had been named
          herein.  Such assuming Person may cause to be signed, and may issue either in its own name (or, if it is the successor to the Company or substantially all assets of the Company, in the name of the Company prior to such succession) any or all of
          the Securities issuable hereunder, in the case of Global Securities, which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such successor corporation instead of the Company and subject to
          all the terms, conditions and limitations in this CVR Agreement prescribed, the Trustee shall authenticate and shall deliver any Securities which previously shall have been
            signed and delivered to the Trustee for authentication, and any Securities which such assuming Person thereafter shall cause to be signed and delivered to the Trustee for that purpose.  All of the Securities so issued shall in all respects have
            the same legal rank and benefit under this CVR Agreement as the Securities theretofore or thereafter issued in accordance with the terms of this CVR Agreement as though all of such Securities had been issued at the date of the execution hereof.

     

    (b)          In case of any such assumption, such changes in phraseology and form (but not in substance) may be made in the Securities thereafter to be issued as may be appropriate.

     

    
      40

      
        

    

    (c)          In the event of any such assumption, the assigning Person shall be discharged from all obligations and covenants under this CVR Agreement and the Securities and may be liquidated and dissolved.

     

    Section 9.3        
      Opinion of Counsel to the Trustee.  The Trustee, subject to the provisions of Sections 4.1 and 4.2, shall receive an Officer’s Certificate and Opinion of Counsel, prepared in accordance with Section 1.2 and Section

          1.3, as conclusive evidence that any such consolidation, merger, sale or conveyance, and any such assumption, and any such liquidation or dissolution, complies with the applicable provisions of this CVR Agreement, and if a supplemental
      agreement is required in connection with such transaction, such supplemental agreement complies with this Article and that there has been compliance with all conditions precedent herein provided for or relating to such transaction.

     

    Section 9.4      
         Successors.  All covenants, provisions and agreements in this CVR Agreement by or for the benefit of the Company, the Trustee or the Holders shall bind and inure to the benefit of their
      respective successors, assigns, heirs and personal representatives, whether so expressed or not.  The Company may assign this CVR Agreement without the prior written consent of the other Parties to this CVR Agreement to one or more of its direct or
      indirect Subsidiaries, provided, however, that, subject to Section 9.2(a)
      and (b), in the event of any such assignment the Company shall remain subject to its obligations and covenants hereunder, including but not limited to its obligation to make the Milestone
      Payment.

     

    ARTICLE 10

      SUBORDINATION

     

    Section 10.1        Agreement to Subordinate.  The Company agrees, and each Holder by accepting a Security hereunder agrees, that the Milestone Payment, all other obligations
      under this CVR Agreement and the Securities and any rights or claims relating thereto (collectively, the “Junior Obligations”) are subordinated in right of payment, to the extent and in the
      manner provided in this Article 10, to the prior payment in full in cash or cash equivalents of all Senior Obligations of the Company (whether outstanding on the date hereof or hereafter
      created, incurred, assumed or guaranteed), and that the subordination is for the benefit of the holders of such Senior Obligations.

     

    Section 10.2      
        Liquidation; Dissolution; Bankruptcy.  Upon any distribution to creditors of the Company in a liquidation or dissolution of the Company or in a bankruptcy, reorganization, insolvency,
      receivership or similar proceeding relating to the Company or its property, in an assignment for the benefit of creditors or any marshaling of the Company’s assets and liabilities:

     

    (a)         holders

          of Senior Obligations will be entitled to receive payment in full in cash or cash equivalents of all Senior Obligations of the Company (including interest after the commencement of any bankruptcy proceeding at the rate specified in the applicable
          Senior Obligation, whether or not permitted under such bankruptcy proceedings) before the Holders will be entitled to receive any payment of any kind with respect to the Junior Obligations; and

     

    
      41

      
        

    

    (b)         until

          all Senior Obligations of the Company (as provided in clause (a) above) are paid in full in cash or cash equivalents, any distribution to which Holders would be entitled but for this Article 10
          will be made to holders of Senior Obligations of the Company, as their interests may appear.

     

    Section 10.3       
      Default on Senior Obligations.  The Company may not make any payment or distribution to any Holder in respect of Junior Obligations or acquire from any Holder for cash or property any Junior
      Obligations:

     

    (a)          if any default on any Senior Obligations exceeding twenty-five million dollars ($25,000,000) in aggregate principal amount would occur as a result of such payment, distribution or acquisition;

     

    (b)          during the continuance of any payment default in respect of any Senior Obligations (after expiration of any applicable grace period) exceeding twenty-five million dollars ($25,000,000) in aggregate principal amount;

     

    (c)          if the maturity of any Senior Obligations representing more than twenty-five million dollars ($25,000,000) in aggregate principal amount is accelerated in accordance with its terms and such acceleration has not been rescinded; or

     

    (d)         following

          the occurrence of any default (other than a payment default, and after the expiration of any applicable grace period) with respect to any Senior Obligations with an aggregate principal amount of more than twenty-five million dollars
          ($25,000,000), the effect of which is to permit the holders of such Senior Obligations (or a trustee or agent acting on their behalf) to cause, with the giving of notice if required, the maturity of such Senior Obligations to be accelerated, for
          a period commencing upon the receipt by the Trustee (with a copy to the Company) of a written notice of such default from the representative of the holders of such Senior Obligations and ending when such Senior Obligations are paid in full in
          cash or cash equivalents or, if earlier, when such default is cured or waived.

     

    Section 10.4       
      When Distribution Must Be Paid Over.

     

    (a)          In the event that the Trustee or any Holder receives any payment of any Junior Obligations at a time when such payment is prohibited by this Article 10, and is notified as such
          by the Company, such payment will be held by the Trustee or such Holder, in trust for the benefit of, and will be paid forthwith over and delivered, upon written request, to, the representative of the holders of Senior Obligations under the
          agreement, indenture or other document (if any) pursuant to which such Senior Obligations may have been issued, as their respective interests may appear, for application to the payment of all such Senior Obligations remaining unpaid to the extent
          necessary to pay such Senior Obligations in full in accordance with their terms, after giving effect to any concurrent payment or distribution to or for the holders of Senior Obligations.

     

    (b)        Any

          amount received by any Holder as a result of direct or indirect credit support for the Junior Obligations from any Affiliate of the Company shall be treated as payments received by such Holder from the Company that are subject to the provisions
          of this Article 10.

     

    
      42

      
        

    

    (c)        With

          respect to the holders of Senior Obligations, the Trustee undertakes to perform only those obligations on the part of the Trustee as are specifically set forth in this Article 10, and
          no implied covenants or obligations with respect to the holders of Senior Obligations will be read into this CVR Agreement against the Trustee.  The Trustee will not be deemed to owe any fiduciary duty to the holders of Senior Obligations, and
          will not be liable to any such holders if the Trustee pays over or distributes to or on behalf of Holders or the Company or any other Person money or assets to which any holders of Senior Obligations are then entitled by virtue of this Article 10, except if such payment is made as a result of the willful misconduct or gross negligence of the Trustee.

     

    Section 10.5   
           Notice by Company.  The Company will promptly notify the Trustee of any facts known to the Company that would cause a payment of any Junior Obligations to violate this Article 10, but failure to give such notice will not affect the subordination of the Junior Obligations to the Senior Obligations as provided in this Article 10.

     

    Section 10.6     
         Subordination Effective Notwithstanding Deficiencies with Respect to Senior Obligations: Waiver of Right to Contest Senior Obligation: Reinstatement of Subordination Provisions.

     

    (a)         The

          Holders hereby agree that subordination provisions contained in this Article 10 are unconditional, irrespective of the validity, regularity or enforceability of the Senior Obligations,
          the absence of any action to enforce the same, any waiver or consent by any holder of Senior Obligations with respect to any provisions thereof, the recovery of any judgment against the Company, any action to enforce the same or any other
          circumstance which might otherwise constitute a legal or equitable discharge or defense.  Without limiting the foregoing, and notwithstanding anything to the contrary contained elsewhere in this CVR Agreement, in the event that the amount of
          Senior Obligations are reduced or diminished for any reason (other than as a result of the payment in cash or cash equivalents thereof), whether because of the applicability of fraudulent conveyance or other applicable Laws, or any other
          invalidity or limitation on the amount of Senior Obligations, the subordination provisions thereof shall apply to the full amount of Senior Obligations (without giving effect to
            any reduction, invalidity or diminution thereof), and the turnover provisions hereunder shall be fully enforceable with respect to the full amount of Senior Obligations (without giving effect to any such reduction, invalidity or diminution
            thereof), even if the effect thereof is that there will be no (or a limited amount of) Senior Obligations to which the Junior Obligations are subrogated after the payment in full in cash of any of the remaining Senior Obligations (without
            giving effect to any reductions, invalidity or diminution thereof, except for reductions as a result of payments thereof in cash or cash equivalents).

     

    
      43

      
        

    

    (b)         The

          Trustee and the Holders agree that they shall not (and hereby waive any right to) take any action to contest or challenge (or assist or support any other Person in contesting or challenging), directly or indirectly, whether or not in any
          proceeding (including in any proceeding commenced by or against any Person under any provision of Title 11 of the United States Code, as now and hereinafter in effect, or any successor statute or under any other state or federal bankruptcy or
          insolvency Law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief), the validity or
          enforceability of the Senior Obligations.

     

    (c)          If any payment made or in respect to the Senior Obligations must be disgorged or returned for any reason, the Senior Obligations shall be reinstated hereunder and for all purposes of this Article

              10 (including the turnover provisions hereof) such payment shall be deemed to have never been made with respect to the Senior Obligations.

     

    Section 10.7       
      Subrogation.  After all Senior Obligations are paid in full in cash or cash equivalents and until the Junior Obligations are paid in full, Holders will be subrogated to the rights of holders
      of Senior Obligations to receive distributions applicable to Senior Obligations to the extent that distributions otherwise payable to the Holders have been applied to the payment of Senior Obligations.  The Holders by accepting the Securities
      acknowledge that to the extent that the Senior Obligations are determined to be unenforceable, or the Senior Obligations are subordinated to other obligations of the Company, such subrogation rights may be impaired.

     

    Section 10.8       
      Relative Rights.  This Article 10 defines the relative rights of Holders and holders of Senior Obligations.  Nothing in this CVR
      Agreement will:

     

    (a)         impair,

          as between the Company and Holders, the obligations of the Company under this CVR Agreement and the Securities; or

     

    (b)         affect

          the relative rights of Holders and creditors of the Company other than their rights in relation to holders of Senior Obligations.

     

    (c)         prevent

          the Trustee or Holder of any Security from exercising all remedies otherwise permitted under this CVR Agreement upon default under this CVR Agreement, subject to the rights, if any, under this Article

              10 of the holders of Senior Obligations to receive cash, property and securities otherwise payable or deliverable to the Trustee or such Holder of CVR

     

    If the Company fails because of this Article 10 to pay any amounts due in respect of the
      Securities on a due date in violation of Section 8.1, the failure is still an Event of Default. Unless prohibited by this Article 10,
      nothing contained in this Article 10 shall prevent the Company from making regularly scheduled payments under this CVR Agreement.

     

    Section 10.9       
      Subordination May Not Be Impaired by Company.  No right of any holder of Senior Obligations to enforce the subordination of the Junior Obligations may be impaired by any act or
      failure to act by the Company or any Holder or by the failure of the Company or any Holder to comply with this CVR Agreement.

     

    Section 10.10     
      Distribution or Notice to Representative.  Whenever a distribution is to be made or a notice given to holders of Senior Obligations, the distribution may be made and the notice given to
      their representative in accordance with the terms of the instrument or other agreement governing such Senior Obligations.  Upon any payment or distribution of assets of the Company referred to in this Article

          10, the Trustee and the Holders will be entitled to rely upon any order or decree made by any court of competent jurisdiction or upon any certificate of such representative or of the liquidating trustee or agent or other Person making
      any distribution to the Trustee or to the Holders for the purpose of ascertaining the Persons entitled to participate in such distribution, the holders of the Senior Obligations and other obligations of the Company, the amount thereof or payable
      thereon, the amount or amounts paid or distributed thereon and all other facts pertinent thereto or to this Article 10.

     

    
      44

      
        

    

    Section 10.11     
      Rights of the Trustee.  Notwithstanding the provisions of this Article 10 or any other provision of this CVR Agreement, the
      Trustee will not be charged with knowledge of the existence of any facts that would prohibit the making of any payment or distribution by the Trustee, and the Trustee may continue to make payments on the Securities, unless the Trustee has received at
      its address for notice specified in Section 1.5 at least five (5) Business Days prior to the date of such payment written notice of facts that would cause the payment of any Junior
      Obligations to violate this Article 10.  Only the Company or a representative of Senior Obligations may give the notice and the Trustee shall be fully protected and shall incur no liability
      prior to receiving said notice.  In the event that the Trustee determines in good faith that further evidence is required with respect to the right of any Person as a holder of Senior Obligations to participate in any payment or distribution pursuant
      to this Article 10, the Trustee may request such person to furnish evidence to the reasonable satisfaction of the Trustee as to the amount of Senior Obligations held by such Person, the extent to which such Person is entitled to participate in such
      payment or distribution and any other facts pertinent to the rights of such Person as it relates to this Article 10, and if such evidence is not furnished, the Trustee may defer any payment
      to such Person pending judicial determination as to the right of such Person to receive such payment. Nothing in this Article 10 will impair or subordinate the claims of, or payments to,
      the Trustee under or pursuant to Section 4.7. The Trustee in its individual or any other capacity may hold Senior Obligations with the same rights it would have if it were not the Trustee.

     

    Section 10.12     
      Authorization to Effect Subordination.  Each Holder, by the Holder’s acceptance of the Securities, authorizes and directs the Trustee on such Holder’s behalf to take such action as may be
      necessary or appropriate to effectuate the subordination as provided in this Article 10, and appoints the Trustee to act as such Holder’s attorney-in-fact for any and all such purposes.  If
      the Trustee (or any other Person acting on behalf of and at the direction of the Majority Holders) does not file a proper proof of claim or proof of debt in the form required in any proceeding referred to in Section 8.2 hereof at least thirty (30) days before the expiration of the time to file such claim, the representatives of the Senior Obligations are hereby authorized to file an appropriate claim for and on behalf of the
      Holders of the Securities.

     

    Section 10.13     Amendments.  The provisions of this Article 10 are expressly made for the benefit of the holders from time to time of the Senior
      Obligations, and may not be amended or modified without the written consent of the representatives of the holders of all Senior Obligations.

     

    [Signature Page Follows]

     

    
      45

      
        

    

    IN WITNESS WHEREOF, the Parties hereto have caused this CVR Agreement to be duly executed, all as of the day and year first above written.

     

    	 	
            BRISTOL-MYERS SQUIBB COMPANY

          
	 	 
	 	
            By:

          	
            /s/ Katherine R. Kelly

          	 
	 	
            Name:

          	
            Katherine R. Kelly

          
	 	
            Title:

          	
            Corporate Secretary

          

    

    

    	 	
            EQUINITI TRUST COMPANY, as the Trustee

          
	 	 
	 	
            By:

          	
            /s/ Martin J. Knapp

          	 
	 	
            Name:

          	
            Martin J. Knapp

          
	 	
            Title:

          	
            Vice President

          

    

    

    
      [Signature Page to CVR Agreement]

    

    

    

    
      
        

    

    
    ANNEX A

     

    THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE CONTINGENT VALUE RIGHTS AGREEMENT (THE “CVR

          AGREEMENT”) HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF A DEPOSITARY OR A SUCCESSOR DEPOSITARY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF.  THIS SECURITY IS NOT EXCHANGEABLE FOR SECURITIES
      REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE CVR AGREEMENT, AND NO TRANSFER OF THIS SECURITY (OTHER THAN A TRANSFER OF THIS SECURITY AS A WHOLE BY THE DEPOSITARY TO A
      NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE CVR AGREEMENT.

     

    UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DIRECT REGISTRATION FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A
      WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR
      DEPOSITARY.  UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”) TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF
      TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS
      IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

     

    BRISTOL-MYERS SQUIBB COMPANY

     

    
      	No.	Certificate for

              	Contingent Value Rights
	CUSIP	[________]	
               

            

    

     

      

    This certifies that __________, or registered assigns (the “Holder”),

      is the registered holder of the number of Contingent Value Rights (“CVRs” or “Securities”) set forth above.  Each CVR entitles the
      Holder, subject to the provisions contained herein and in the CVR Agreement referred to on the reverse hereof, to payments from Bristol-Myers Squibb Company, a Delaware corporation (the “Company”),

      in the amounts and in the forms determined pursuant to the provisions set forth on the reverse hereof and as more fully described in the CVR Agreement referred to on the reverse hereof.  Such payments shall be made by the Company on the Milestone Payment Date, as defined in the CVR Agreement referred to on the reverse hereof, in accordance with the terms of the CVR Agreement.

     

    
      A-1

      
        

    

    Payment of any amounts pursuant to this CVR certificate shall be made only to the registered Holder (as defined in the CVR Agreement) of this CVR
      certificate.  Such payment shall be made at an office or agency maintained by the Company for such purpose, in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts; provided,
      however, the Company may pay such amounts by wire transfer or check payable in such money.  Equiniti Trust Company has been initially appointed as Paying Agent at its office or agency in 1110 Centre Pointe Curve, Suite 101 Mendota Heights, Minnesota
      55120-4101.

     

    Reference is hereby made to the further provisions of this CVR certificate set forth on the reverse hereof, which further provisions shall for all
      purposes have the same effect as if set forth at this place.

     

    Unless the certificate of authentication hereon has been duly executed by the Trustee referred to on the reverse hereof, this CVR certificate shall not
      be entitled to any benefit under the CVR Agreement, or be valid or obligatory for any purpose.

     

    IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

     

    Dated:   [•]

     

    
      	
               

            	By:	
               

            
	
               

            	
               

            	Name:

              
	
               

            	
               

            	Title:

    

     

      

    [Form of Reverse of CVR certificate]

     

    1.          This CVR certificate is issued under and
          in accordance with the Contingent Value Rights Agreement, dated as of November 20, 2019 (the “CVR Agreement”), between the Company and Equiniti Trust Company, a limited trust company
          organized under the laws of the State of New York, as trustee (the “Trustee,” which term includes any successor Trustee under the CVR Agreement), and is subject to
          the terms and provisions contained in the CVR Agreement, to all of which terms and provisions the Holder of this CVR certificate consents by acceptance hereof.  The CVR Agreement is hereby incorporated herein by reference and made a part hereof. 
          Reference is hereby made to the CVR Agreement for a full statement of the respective rights, limitations of rights, duties, obligations and immunities thereunder of the Company, the Trustee and the Holders of the CVRs.  All capitalized terms used
          in this CVR certificate without definition shall have the respective meanings ascribed to them in the CVR Agreement.  Copies of the CVR Agreement can be obtained by contacting the Trustee.

     

    2.           On the Milestone Payment Date, the
          Company shall make the payments required by Section 3.1(c) of the CVR Agreement to the Trustee, for further distribution by the Trustee to the Holders in accordance with Section 3.1(c) of the CVR Agreement.

     

    
      A-2

      
        

    

    3.           In the event of any conflict between
          this CVR certificate and the CVR Agreement, the CVR Agreement shall govern and prevail.

     

    4.           The Milestone Payment, if any, and
          interest thereon, if any, shall be payable by the Company in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts; provided,
          however, that such amounts may be paid check or wire transfer payable in such money.  Equiniti Trust Company has been initially appointed as Paying Agent at its office or agency in 1110
          Centre Pointe Curve, Suite 101 Mendota Heights, Minnesota 55120-4101.

     

    5.           If an Event of Default occurs and is
          continuing, either the Trustee by notice in writing to the Company or the Trustee upon the written request of the Majority Holders (by notice in writing to the Company (and to the Trustee if given by the Majority Holders), shall bring suit in
          accordance with the terms and conditions of the CVR Agreement to protect the rights of the Holders, including to obtain payment of all amounts then due and payable, with interest at the Default Interest Rate from the date of the Event of Default
          through the date payment is made or duly provided for.

     

    6.           No reference herein to the CVR
          Agreement and no provision of this CVR certificate or of the CVR Agreement shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay any amounts determined pursuant to the terms hereof and of the CVR
          Agreement at the times, place and amount, and in the manner, herein prescribed.

     

    7.           The Milestone Payment or any other
          right, claim or payment of any kind under this CVR certificate, if any, shall be subordinated in right of payment, as set forth in Article 10 of the CVR Agreement, to the prior payment in full in cash or cash equivalents of all Senior Obligations
          whether outstanding on the date of the CVR Agreement or thereafter incurred.

     

    8.          As provided in the CVR Agreement and
          subject to certain limitations therein set forth, the transfer of the CVRs represented by this CVR certificate is registrable on the Security Register, upon surrender of this CVR certificate for registration of transfer at the office or agency of
          the Company maintained for such purpose, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in
          writing, and thereupon one or more new CVR certificates or Direct Registration Securities, for the same amount of CVRs, will be issued to the designated transferee or transferees.  The Company hereby initially designates the office of Trustee at
          1110 Centre Pointe Curve, Suite 101 Mendota Heights, Minnesota 55120-4101 as the office for registration of transfer of this CVR certificate.

     

    9.           As provided in the CVR Agreement and
          subject to certain limitations therein set forth, this CVR certificate is exchangeable for one or more CVR certificates or Direct Registration Securities representing the same
            number of CVRs as represented by this CVR certificate as requested by the Holder surrendering the same.

     

    
      A-3

      
        

    

    10.         No service charge will be made for any
          registration of transfer or exchange of CVRs, but the Company may require payment of a sum sufficient to cover all documentary, stamp or similar issue or transfer taxes or other governmental charges payable in connection with any registration of
          transfer or exchange.

     

    11.         Prior to the time of due presentment of
          this CVR certificate for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this CVR certificate is registered as the owner hereof for all purposes, and neither the
          Company, the Trustee nor any agent shall be affected by notice to the contrary.

     

    12.         Neither the Company nor the Trustee has
          any duty or obligation to the holder of this CVR certificate, except as expressly set forth herein or in the CVR Agreement.

     

    
      A-4

      
        

    

    TRUSTEE’S CERTIFICATE OF AUTHENTICATION

     

    This is one of the Global Securities referred to in the within-mentioned CVR Agreement.

     

    
      	
               

            	[__________], as the Trustee
	
               

            	
               

            	
               

            
	
              Dated:  [•]

            	
               

            	
               

            
	 	 	 
	 	By:	 
	
               

            	
               

            	Authorized Signatory

    

     

      

    
      A-5

      
        

    

    
    Annex B

     

    Form of Assignment and Assumption Agreement

     

    ASSIGNMENT AND ASSUMPTION AGREEMENT, made as of [_____], [_____] (this “Agreement”), between
      Bristol-Myers Squibb Company, a Delaware corporation (“Assignor”), and [_____], a [___] (“Assignee”).  Unless otherwise defined
      herein, capitalized terms used in this Agreement shall have the meanings given to them in the CVR Agreement referred to below.

     

    W I T N E S S E T H:

     

    WHEREAS, Assignor and Equiniti Trust Company, a limited trust company organized under the laws of the state of New York, as trustee (the “Trustee”) are parties to a Contingent Value Rights Agreement dated as of November 20, 2019 (the “CVR Agreement”); and

     

    WHEREAS, Assignor and Assignee desire to execute and deliver this Agreement evidencing the assignment to Assignee of due and punctual payment of the
      Milestone Payment and the performance and observance of every term, covenant, obligation and condition of the CVR Agreement of Assignor to be performed and observed and the assumption thereof by Assignee.

     

    NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which is hereby
      acknowledged, Assignor and Assignee hereby agree as follows:

     

    
      
        	1.	
                Assignment.  Effective as of [______] (the “Assignment Date”), Assignor hereby assigns to Assignee, and Assignee hereby accepts the assignment of, the due and punctual payment of the Milestone Payment and the performance and observance of all
                    terms, covenants, obligations and conditions of the CVR Agreement on the part of Assignor to be performed or observed.

              

      

    

     

    
      
        	2.	
                Assumption.  Effective as of the Assignment Date, Assignee hereby
                    assumes the due and punctual payment of the Milestone Payment and the performance and observance of all terms, covenants, obligations and conditions of the CVR Agreement on the part of Assignor to be performed or observed.

              

      

    

     

    
      
        	3.	
                Successors and Assigns.  This Agreement shall be binding upon and
                    shall inure to the benefit of the respective parties hereto and their respective successors and assigns.

              

      

    

     

    
      
        	4.	
                Governing Law.  This Agreement shall be governed by, construed and
                    enforced in accordance with the laws of New York, without giving effect to the principles of conflicts of laws thereof.

              

      

    

     

    
      
        	5.	
                Counterparts.  This Agreement may be executed in one or more
                    counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.

              

      

    

     

    
      B-1

      
        

    

    IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, all as of the day and year first above written.

     

    
      	 	
              BRISTOL-MYERS SQUIBB COMPANY

            
	 	 
	 	
              By:

            	 
	 	 	
              Name:

            
	 	

            	
              Title:

            
	 	 	 
	 	
              [ASSIGNEE]

            
	 	 	 
	 	
              By:

            	 
	 	 	
              Name:

            
	 	

            	
              Title:

            

    

     

      

     

      

  

  
    B-2Exhibit 4.2

  

   

    EXECUTION VERSION

  

  

  

  
    ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT

     

    This Assignment, Assumption and Amendment Agreement (this “Agreement”) is
      made and entered into as of November 20, 2019, by and among Celgene Corporation, a Delaware corporation (“Assignor”), Bristol-Myers Squibb Company, a Delaware corporation (“Assignee”), American Stock Transfer & Trust Company, LLC, a New York limited liability company, as trustee (the “Existing Trustee”), and Equiniti Trust Company, a limited trust organized under the laws of the State of New York (the “New Trustee”).  All
      capitalized terms used but not defined in this Agreement have the meanings given to them in the CVR Agreement (as defined below).

     

    WHEREAS, Assignor and the Existing Trustee entered into a Contingent Value Rights Agreement, dated as of October 15, 2010 (as amended, supplemented or
      otherwise modified from time to time in accordance with its terms, the “CVR Agreement”);

     

    WHEREAS, Assignor, Assignee and Burgundy Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Assignee (“Merger Sub”), are parties to that certain Agreement and Plan of Merger, dated as of January 2, 2019 (as amended, supplemented or otherwise modified from time to time in
      accordance with its terms, the “Merger Agreement”), pursuant to which, among other things, Merger Sub merged with and into Assignor at the Merger Effective Time (as defined
      in the Merger Agreement), with Assignor continuing as the surviving corporation and a direct wholly-owned subsidiary of Assignee (the “Merger”);

     

    WHEREAS, substantially contemporaneously with the execution and delivery of this Agreement, Assignee has, in accordance with Section 1.2 and Section
      9.3 of the CVR Agreement, delivered an Officer’s Certificate and Opinion of Counsel to the Trustee, as conclusive evidence that the matters contemplated by Section 1 or Section 2 below, respectively, comply with the applicable provisions of the CVR
      Agreement and that there has been compliance with all conditions precedent provided for or relating to the foregoing under the CVR Agreement;

     

    WHEREAS, pursuant to Section 6.1 of the CVR Agreement, the Company and the Trustee may, without the consent of the Holders, enter into one or more
      amendments to the CVR Agreement to, among other things, make any change that does not adversely affect the interests of the Holders or to evidence the succession of another Person to the Company and the assumption by any such successor of the
      covenants of the Company herein and in the Securities;

     

    WHEREAS, in connection with the Merger, (a) Assignor and the Existing Trustee desire to amend the CVR Agreement to clarify that the calculation of the
      combined capital and surplus of the Trustee shall include the Trustee and its affiliates; (b) Assignor and the Existing Trustee desire to amend the CVR Agreement to allow for the Securities to be listed on the New York Stock Exchange or any other
      national securities exchange following the Merger Effective Time; (c) Assignor and the Existing Trustee desire to amend the CVR Agreement to allow for Assignee, the parent company of Assignor following the Merger, to assume all of its rights, duties,
      obligations, liabilities and interests in, to and under the CVR Agreement; and (d) the parties desire to execute and deliver this Agreement as evidence of the agreement and consent of such assignment and assumption to Assignee;

     

    

    
      
        

    

    
    WHEREAS, following the consummation of the Merger, Assignor desires to assign all of its rights, duties, obligations, liabilities and interests in, to
      and under the CVR Agreement to Assignee, and Assignee desires to assume all such rights, duties, obligations, liabilities and interests of Assignor in, to and under the CVR Agreement, which assignment shall be effective immediately following the
      listing of the Securities on the New York Stock Exchange;

     

    WHEREAS, Section 4.10(b) of the CVR Agreement provides that the Trustee may at any time resign by giving written notice to the Assignor, effective
      upon the appointment of a successor trustee pursuant to Section 4.11 of the CVR Agreement; and

     

    WHEREAS, immediately following the Merger Effective Time, the Existing Trustee desires to resign as trustee of the CVR Agreement, the Company desires
      to appoint the New Trustee as successor trustee of the CVR Agreement, and the New Trustee is willing to accept such appointment as successor trustee under the CVR Agreement.

     

    NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements and other good and valuable consideration, the parties, each
      intending to be legally bound, hereby agree as follows:

     

    1. Amendment to Section 4.9, 7.7 and 9.4 of the CVR Agreement and Related Agreements.

     

    
      
        	

              	a)	
                On the date hereof, effective immediately following the Merger Effective Time, the Assignor and the Existing Trustee hereby agree to amend and restate the first sentence of
                  Section 4.9 of the CVR Agreement as follows:

              

      

    

     

    “There shall at all times be a Trustee hereunder which satisfies the applicable requirements of Sections 310(a)(1) and (5) of the Trust Indenture Act
      and which, along with its Affiliates, has a combined capital and surplus of at least one hundred fifty million dollars ($150,000,000).”

     

    
      
        	

              	b)	
                On the date hereof, effective immediately following the Merger Effective Time, the Assignor and the Existing Trustee hereby agree to amend and restate Section 7.7 of the CVR
                  Agreement in its entirety as follows:

              

      

    

     

    “The Company hereby covenants and agrees to use reasonable best efforts to cause the Securities to be approved for listing (subject to notice of
      issuance) for trading on the New York Stock Exchange or other national securities exchange and will use its reasonable best efforts to maintain such listing for so long as any CVRs remain Outstanding.”

     

    
      
        	

              	c)	
                Without limiting the generality of Section 1(b) above, each party hereto acknowledges and agrees that Assignee, subject to, and conditioned upon, the occurrence of the Merger
                  Effective Time, intends to delist the CVRs from the Nasdaq and list the CVRs on the New York Stock Exchange and consents to the same.

              

      

    

     

    
      
        	

              	d)	
                On the date hereof, effective immediately following the Merger Effective Time, the Assignor and the Existing Trustee hereby agree to amend and restate Section 9.4 of the CVR
                  Agreement in its entirety as follows:

              

         

        

      

    

    
      2

      
        

    

    “All covenants, provisions and agreements in this CVR Agreement by or for the benefit of the Company, the Trustee or the Holders shall bind and inure
      to the benefit of their respective successors, assigns, heirs and personal representatives, whether so expressed or not. The Company may assign this CVR Agreement without the prior written consent of the other Parties to this CVR Agreement to one or
      more of its Affiliates, provided, however, that in the event of any such assignment the Company shall, unless and to the extent performed by any such assignee, remain subject to its obligations and covenants hereunder, including but not limited to
      its obligation to make any Net Sales Payments and any Milestone Payments.”

     

    2. Assignment and Assumption.

     

    
      
        	

              	a)	
                Subject to, and conditioned upon the occurrence of the Merger Effective Time, and effective as of immediately following the listing of the Securities on the New York Stock
                  Exchange, Assignor hereby assigns all of its rights, duties, obligations, liabilities and interests in, to and under the CVR Agreement to Assignee, and Assignee hereby assumes all such rights, duties, obligations, liabilities and
                  interests of Assignor in, to and under the CVR Agreement, including, without limitation, the due and punctual payment of the Securities, according to their tenor, and the due and punctual performance and observance of all of the covenants
                  and conditions of the CVR Agreement to be performed or observed by Assignor (collectively, the “Assignment and Assumption”).

              

      

    

     

    
      
        	

              	b)	
                Each of the parties hereto acknowledges, agrees and consents to, subject to and conditioned upon the Assignment and Assumption, Assignor succeeding to and being substituted for
                  Assignee with the same effect as if Assignor had been named in the CVR Agreement as the “Company” for all purposes under the CVR Agreement.  Without limiting the generality of the foregoing, (i) each of the parties, for the avoidance of
                  doubt, acknowledges and agrees that Assignee shall succeed to and be substituted for Assignor automatically, without any further action of any party hereto, at the Merger Effective Time, (ii) the Existing Trustee (prior to the appointment
                  and acceptance of the New Trustee as trustee under the CVR Agreement pursuant to Section 3) and the New Trustee (from and after the appointment and acceptance of the New Trustee as trustee pursuant to Section 3) agree to take any of the
                  foregoing actions as if an assumption occurred pursuant to Section 9.1(i) and the other relevant provisions of the CVR Agreement in connection with the matters described by this Section 2 and (iii) the CVR Agreement shall automatically be
                  deemed to be modified accordingly to give effect to the matters described by this Section 2.

              

      

    

     

    3. Resignation of Existing Trustee; Appointment of New Trustee.

     

    
      
        	

              	a)	
                Subject to, and conditioned upon, and effective as of immediately following, the Merger Effective Time, pursuant to Section 4.10(b) of the CVR Agreement, the Existing Trustee
                  hereby notifies the Assignor that the Existing Trustee is resigning as trustee under the CVR Agreement.

              

      

    

     

    
      
        	

              	b)	
                Subject to, and conditioned upon, and effective as of immediately following, the Merger Effective Time, (i) the Assignor hereby accepts the resignation of the Existing Trustee as
                  trustee under the CVR Agreement and (ii) pursuant to Section 4.10(e) of the CVR Agreement, the Assignor hereby appoints the New Trustee as trustee under the CVR Agreement, to succeed to, and hereby vests the New Trustee with, all the
                  estates, properties, rights powers, trusts, duties and obligations of the Trustee under the CVR Agreement with like effect as if originally named as trustee in the CVR Agreement.

              

         

        

      

    

    
      3

      
        

    

    
      
        	

              	c)	
                The New Trustee hereby accepts the appointment as trustee under the CVR Agreement and shall hereby be vested with all the estates, properties, rights powers, trusts, duties and
                  obligations of the Trustee under the CVR Agreement with like effect as if originally named as trustee in the CVR Agreement.  The New Trustee hereby represents and warrants that it is qualified and eligible under Article 4 of the CVR
                  Agreement to act as trustee under the CVR Agreement.

              

      

    

     

    
      
        	

              	d)	
                From and after giving effect to the appointment and acceptance of the New Trustee as trustee under the CVR Agreement until otherwise amended, modified or supplemented in
                  accordance with the CVR Agreement, references in the CVR Agreement to “Corporate Trust Office” or other similar terms shall be deemed to refer to the corporate trust office of the New Trustee at 1110 Centre Pointe Curve, Suite 101 Mendota
                  Heights, Minnesota 55120-4101 or any other office of the New Trustee at which, at any particular time, its corporate trust business shall be administered.

              

      

    

     

    4. Successors and Assigns. This Agreement shall be binding upon and shall inure to the
      benefit of the respective parties hereto and their respective successors and assigns.

     

    5. Governing Law. This Agreement shall be governed by and construed in accordance with the
      laws of the State of New York including, without limitation, Sections 5-1401 and 5-1402 of the New York General Obligations Law without regard to the conflict of laws principles thereof.

     

    6. No Further Amendment to CVR Agreement. Except as specifically modified or amended by
      this Agreement, the CVR Agreement shall remain unaltered and in full force and effect and the respective terms, conditions and covenants thereof are herein in all respects confirmed.  Whenever the CVR Agreement is referred to in any agreement,
      document or other instrument, such reference will be to the CVR Agreement as modified and/or amended by this Agreement.

     

    7. Amendment. This Agreement may not be changed, modified, discharged or terminated orally
      or in any manner other than by an agreement in writing signed by the parties hereto or their respective successors and assigns specifically identifying such writing as an amendment to this Agreement.

     

    8. Severability. In case any provision in this Agreement are held to be invalid, illegal or
      unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

     

    9. Counterparts. This Agreement may be signed in any number of counterparts with the same
      effect as if the signatures to each counterpart were upon a single instrument, and all such counterparts together will be deemed an original of this Agreement.

     

    [Signature Page Follows]

     

    

    
      4

      
        

    

    IN WITNESS WHEREOF, each of the undersigned has executed this Assignment and Assumption Agreement as of the date first written above.

    

    

    	 	
            ASSIGNOR:

          
	 	 
	 	
            CELGENE CORPORATION

          
	 	 	 
	 	
            By:

          	
            
              /s/ Katherine R. Kelly

            

          
	 	
            Name:

          	
            Katherine R. Kelly

          
	 	
            Title:

          	
            Secretary

          

    

    

    	 	
            ASSIGNEE:

          
	 	 
	 	
            BRISTOL-MYERS SQUIBB COMPANY

          
	 	 	 
	 	
            By:

          	
            
              /s/ Katherine R. Kelly

            

          
	 	
            Name:

          	
            Katherine R. Kelly

          
	 	
            Title:

          	
            Secretary

          

    

    

    	 	
            EXISTING TRUSTEE:

          
	 	 
	 	
            AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC

          
	 	 	 
	 	
            By:

          	
            
              /s/ Michael Nespoli

            

          
	 	
            Name:

          	
            Michael Nespoli

          
	 	
            Title:

          	
            Executive Director

          

    

    

    
      [Signature Page to Assignment and Assumption Agreement]

      

    

    
      
        

    

    	 	
            NEW TRUSTEE:

          
	 	 
	 	
            EQUINITI TRUST COMPANY

          
	 	 	 
	 	
            By:

          	
            
              /s/ Martin Knapp

            

          
	 	
            Name:

          	
            Martin Knapp

          
	 	
            Title:

          	
            Vice President

          

     

    

     
      [Signature Page to Assignment and Assumption Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]